

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Chemical peels for acne vulgaris: a systematic review of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019607
Article Type:	Research
Date Submitted by the Author:	13-Sep-2017
Complete List of Authors:	Chen, Xiaomei; Sichuan University West China Hospital, Department of Dermatology & Venereology Wang, Sheng; Sichuan University West China Hospital, Department of Dermatology & Venereology Yang, Ming; The Center of Gerontology and Geriatrics; Li, Li; Sichuan University West China Hospital, Department of Dermatology & Venereology
Keywords:	chemical peeling, acne vulgaris, systematic review, treatment, comedone, papule

SCHOLARONE™
Manuscripts

View Only

Title Page

Title

Chemical peels for acne vulgaris: a systematic review of randomized controlled trials

Authors

Xiaomei Chen M.D., Sheng Wang M.D., Ming Yang M.D., Li Li M.D.

Affiliations and locations of all authors

Xiaomei Chen: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Sheng Wang: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Ming Yang: The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China

Li Li: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Corresponding author

Li Li, M.D.: Department of Dermatology & Venereology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China.

Telephone: +86 28 85423315; Fax: +86 28 85423315; Email:

hxskincos2017@qq.com

Word counts

Manuscript: 3895 words

Abstract

Objective: Systematically evaluate current evidence from randomized controlled trials (RCTs) regarding the effectiveness of chemical peeling agents for the treatment of acne vulgaris.

Methods: Standard Cochrane methodological procedures were used. We searched MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE via OvidSP through April 2017. Reviewers independently assessed eligibility and risk of bias, and extracted data from the included RCTs. Meta-analysis was not possible due to the significant clinical heterogeneity across studies.

Results: Twelve RCTs (387 participants) were included in our analysis. Effectiveness was equivalent for the following agents: trichloroacetic acid versus salicylic acid (SA); glycolic acid (GA) versus amino fruit acid; SA versus pyruvic acid; GA versus SA; GA versus Jessner's solution (JS); and lipohydroxy acid versus SA. The combination of SA and mandelic acid peels was superior to GA peeling; with GA peeling being superior to a placebo. SA peeling may be superior to JS peeling to treat comedones, but is less effective than phototherapy to treat pustules. The methodological quality of all included RCTs was very low to moderate, with possible biasing of results.

1
2
3
4 **Conclusions:** Commonly used chemical peels have similar effectiveness for the
5
6 treatment of mild-to-moderate acne vulgaris and are well-tolerated. Further evaluation
7
8 is needed for premixed peels and to identify optimal regimens.
9

10 **Keywords:** chemical peeling; acne vulgaris; systematic review; treatment; comedone;
11
12 papule; pustule
13
14

15 16 17 **ARTICLE SUMMARY**

- 18 ● Chemical peeling is widely used for acne vulgaris.
- 19 ● Chemical peeling is a useful and well-tolerated method for improving acne
20 lesions. Commonly used chemical peels have similar effects, but data regarding
21 premixed peeling agents are limited.
- 22 ● Premixed peels and optimal regimens need further evaluation.
23
24
25
26
27

28 29 **INTRODUCTION**

30
31
32 Acne is one of the most common skin disorders, being prevalent in most ethnic
33 populations around the world.¹ Acne is most prevalent among adolescents, affecting
34 85% to 90% of adolescents, and may persist into adulthood in some patients.^{2,3} Acne
35 vulgaris can negatively affect an individual's appearance and self-esteem, causing
36 anxiety, depression, poor quality of life, and even suicidal ideation.^{1,2} The skin
37 lesions of acne vulgaris are classified as either non-inflammatory lesions (comedones)
38 or inflammatory lesions (papules, pustules, nodules, and cysts). The treatment of acne
39 vulgaris includes systemic therapies (oral antibiotics and retinoid), topical therapies
40 (benzoyl peroxide) and physical modalities (laser therapy and chemical peeling).
41
42
43
44
45
46
47
48
49
50
51
52
53

54 Chemical peeling is a skin resurfacing procedure commonly used for facial
55
56

rejuvenation and esthetics.³ Chemical peeling, which can be traced back to ancient Egypt, induces a manageable injury to the skin, with subsequent regeneration of a new epidermal layer remodeling of the dermal tissues.⁴ The depth of injury is determined by the concentration of acid used, and by the type of vehicle, buffering and contact time with the skin. Chemical peels are, therefore, classified as superficial (destroying the epidermis), moderate (destroying the papillary dermis and upper reticular dermis) or deep (destroying part or all of the mid-reticular dermis).⁵ Although often used to treat acne, chemical peeling is also widely used as a cosmetic treatment for melasma, photoaging and lentigines.⁵ Superficial peels are generally used for acne vulgaris, whereas deep peels are used to treat acne scars. Commonly used agents for chemical peels are summarized in Table 1.

Table 1. The commonly used chemical peels for acne vulgaris

Chemical peels	Abbreviations
α -hydroxy acid	AHA
Amino fruit acid	AFA
Glycolic acid	GA
Mandelic acid	MA
Tartaric acid	TA
β -hydroxy acid	BHA
Salicylic acid	SA
Azelaic acid	AZA
Lipohydroxy acid	LHA
Jessner's solution*	JS
Pyruvic acid	PA
Retinoic acid	RA
Trichloroacetic acid	TCA

*Jessner's solution is a premixed formula containing 14% salicylic acid, 14% lactic acid, and 14% resorcinol.

The exact pathogenesis of acne vulgaris remains unclear. However, the proliferation of *Propionibacterium acnes*, increased levels of inflammatory cytokines and sebum

1
2
3
4 production, and follicular hyperkeratinization are all involved.³ Chemical peels have
5
6 antibacterial, anti-inflammatory, keratolytic, and comedolytic effects, and can reduce
7
8 sebum production. Therefore, chemical peels have been widely used in the treatment
9
10 of acne vulgaris, either as a supplementary or maintenance therapy.^{3 5 6}

11
12
13 Despite the wide application of chemical peels in clinical practice, evidence regarding
14
15 their effectiveness in the treatment of acne vulgaris is limited. In a 2016
16
17 recommendation for the treatment of acne vulgaris, chemical peels were supported by
18
19 level B evidence, namely “inconsistent or limited-quality patient-oriented evidence”.⁷
20
21 This recommendation was based on the evaluation of two trials and previously
22
23 published guideline, and only included research from the PubMed and the Cochrane
24
25 Library databases, from May 2006 through September 2014. Therefore, potential
26
27 evidence from other important medical databases was possibly omitted. In addition,
28
29 new randomized controlled trials (RCT) have been conducted after September
30
31 2014.⁸⁻¹⁵ Therefore, we conducted a systematic review to summarize current evidence
32
33 from the RCTs that regarding the effectiveness of chemical peeling in the treatment of
34
35 acne vulgaris and to evaluate the validity of the aforementioned recommendations.
36
37
38
39
40
41
42

43 **METHODS**

44 **Systematic search of the literature**

45
46
47 This review was performed according to the guidelines for the Preferred Reporting
48
49 Items for Systematic Reviews and Meta-Analysis protocols (PRISMA)¹⁶ and the
50
51 Standard Cochrane methodological procedures.¹⁷ The following databases were
52
53
54
55
56

1
2
3 searched up to April 25, 2017, using the strategy summarized in Supplementary Table
4
5
6 1: MEDLINE via OvidSP (from 1946); EMBASE via OvidSP (from 1974); and the
7
8
9 Cochrane Central Register of Controlled Trials (CENTRAL) 2017, Issue 4.

10
11 We also handsearched all bibliographies of included and excluded studies and
12
13
14 previous systematic reviews to identify further relevant trials.
15

16 **Inclusion and exclusion criteria**

17
18
19 We included all RCTs addressing any chemical peel (compared to placebo or any
20
21
22 other treatment) for the treatment of acne vulgaris in any study population. Excluded
23
24
25 were studies that recruited patients with sequelae of acne, such as post-inflammatory
26
27
28 dyschromia or scarring, evaluated the combined effects of chemical agents and other
29
30
31 therapies, such as laser therapy, were quasi-RCTs, and were not published in English.
32

33 **Selection of studies**

34
35
36 Two authors (X.C. and M.Y.) independently reviewed the titles and abstracts
37
38
39 identified from the searches and selected possible relevant studies. After reviewing the
40
41
42 full text of these studies, the two authors independently decided on studies to be
43
44
45 included and excluded, recording reasons for the exclusion. Any discrepancy in
46
47
48 selection was resolved through discussion.
49

50 **Data extraction**

51
52
53 Two authors (X.C. and M.Y.) independently extracted the information from included
54
55
56 studies using the “characteristics of included studies form” recommended by the
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cochrane Handbook for Systematic Review of Interventions.¹⁷ Another author (WS) verified and compared the data extraction forms.

Assessment of risk of bias in included trials

Two authors (X.C. and M.Y.) independently evaluated the risk of bias of included trials, using the methods recommended by the Cochrane Handbook for Systematic Review of Interventions.¹⁷ Discrepancies were resolved through discussion. The Cochrane risk of bias for each included trial was classified as low, high, or unclear.

Measure of treatment effects

Dichotomous outcomes (such as the percentage of meaningful improvement of the total number of lesions) were reported, when possible, as risk ratios (RR), with the associated 95% confidence intervals (CI), with continuous outcomes (such as the number of inflammatory lesions) reported as a mean difference (MD), with the associated 95% CI.

Heterogeneity and data synthesis

Because of the significant clinical heterogeneity between the included RCTs, it was not possible to merge the data from different trials for meta-analysis.

RESULTS

Description of studies

We identified 605 articles in the initial search, after removing duplicates. Of these,

1
2
3
4 586 were discarded after screening the titles and abstracts, leaving 19 studies for full
5
6 view, with another seven excluded at this stage. Reasons for exclusion were
7
8 summarized in Supplementary Table 2. Our final analysis included 12 RCTs,
9
10 providing data from 387 participants. The PRISMA diagram for study selection is
11
12 presented in Figure 1. Relevant characteristics of the included RCTs are summarized
13
14 in Table 2.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2. Summary of relevant characteristics of included studies

Studies	Publication year	Study design	Country	Sample size	Women (%)	Fitzpatrick skin type	Severity of acne	Interventions	Main outcomes	Follow-up (weeks)
Abdel et al. ⁸	2015	Single-center, double-blind, split-face RCT	Egypt	20	85	III, IV, V	Mild to moderate	25% TCA versus 30% SA	<ul style="list-style-type: none"> ✧ Percentage of total/ good/ fair/ poor improvement of total lesions ✧ Percentage of total/ good/ fair/ poor improvement of non-inflammatory lesions ✧ Percentage of total/ good/ fair/ poor improvement of inflammatory lesions ✧ Reduction of lesion counts ✧ Adverse events 	10
Alba et al. ⁹	2017	Single-center, single-blind RCT	Brazil	22	41	II, III, IV, VI	Mild to moderate	10% SA versus phototherapy	<ul style="list-style-type: none"> ✧ Comedone counts ✧ Papule counts ✧ Pustule counts 	10
Bae et al. ¹⁰	2013	Single-center, single-blind, split-face RCT	Korea	13	0	III or IV	Mild to moderate	30% SA versus JS	<ul style="list-style-type: none"> ✧ Number of non-inflammatory lesions ✧ Number of inflammatory lesions ✧ Self-reported good/ moderate/ mild/ no improvement of all lesions ✧ Adverse events 	8
Dayal et al. ¹¹	2017	Single-center, single-blind RCT	India	40	35	N/A	Mild to moderate	30% SA versus JS	<ul style="list-style-type: none"> ✧ Comedone counts ✧ Overall percentage decrease in mean comedone counts ✧ Papule counts ✧ Overall percentage decrease in mean papule counts ✧ Pustule counts ✧ Overall percentage decrease in mean pustules 	12

Author	Year	Study Design	Country	n1	n2	Severity	Comparison	Outcomes	Count
EI Refaei et al. ¹²	2015	Single-center, open-label RCT	Egypt	40	80	I, II, III, IV	Mild to very severe	20% SA + 10% MA versus 35% GA	20
Ilknur et al. ¹⁸	2010	Single-center, single-blind, split-face RCT	Turkey	30	N/A	II, III	Mild to moderate	GA versus AFA	24
Jaffary et al. ¹³	2016	Multi-center, single-blind RCT	Iran	86	92	N/A	Mild to moderate	30% SA versus 50% PA	8
Kaminaka et al. ¹⁴	2014	Single-center, double-blind, split-face RCT	Japan	25	64	N/A	Moderate to severe	40% GA versus Placebo	10
Kessler et al. ¹⁹	2008	Single-center, double-blind, split-face RCT	American	20	65	N/A	Mild to moderate	30% GA versus 30% SA	20

- counts
- ✧ Michaelsson acne score (MAS)
- ✧ Percentage decrease in mean MAS
- ✧ Percentage of good/ fair/ poor response
- ✧ Adverse events
- ✧ Comedone counts
- ✧ Papule counts
- ✧ Pustule counts
- ✧ Percentage of improvement in comedones/ papules/ pustules/ the total acne score
- ✧ Adverse events
- ✧ Non-inflammatory lesion counts
- ✧ Inflammatory lesion counts
- ✧ Patients' choice for the future treatment
- ✧ Adverse events
- ✧ Comedone counts
- ✧ Papule counts
- ✧ Pustule counts
- ✧ Percentage of excellent/ good/ fair/ poor improvement of all lesions
- ✧ Acne severity index (ASI)
- ✧ Percentage of patient satisfaction
- ✧ Adverse events
- ✧ Non-inflammatory lesion counts
- ✧ Inflammatory lesion counts
- ✧ Total lesion counts
- ✧ Percentage of excellent/ good/ fair/ bad improvement of all lesions
- ✧ Bioengineering measurements
- ✧ Adverse events
- ✧ Mean number of all lesions
- ✧ Reduction of all lesions
- ✧ Percentage of good/ fair/ poor improvement of all lesions

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Kim et al. ²⁰	1999	Single-center, single-blind, split-face RCT	Korea	26	84.6	III, IV	Mild to moderate	to	70%	GA	<ul style="list-style-type: none"> ✧ Self-reported overall improvement ✧ Adverse events ✧ Percentage of patients' who achieving improvement of acne scores of 0.5 or more ✧ Self-reported overall improvement ✧ Patients' choice for the future treatment ✧ Adverse events 	8
Leheta et al. ²¹	2009	Single-center, single-blind, RCT	Egypt	45	N/A	II, III, IV	Mild to moderate	to	20%	TCA	<ul style="list-style-type: none"> ✧ Acne severity score ✧ Mean remission period ✧ Percentage of marked/ moderate response ✧ Self-reported cost-effective ratio ✧ Adverse events 	48
Levesque et al. ¹⁵	2011	Single-center, open-label, split-face RCT	American	20	95	N/A	N/A			LHA (5% or 10%) versus SA (20% or 30%)	<ul style="list-style-type: none"> ✧ Reduction of non-inflammatory lesions ✧ Inflammatory lesion counts ✧ Global acne assessment ✧ Adverse events 	14

AFA: Amino fruit acid; AZA: Azelaic acid; GA: Glycolic acid; JS: Jessner's solution; LHA: Lipohydroxy acid; MA: Mandelic acid; PA: Pyruvic acid; PDL: pulsed dye laser; RCT: Randomized controlled trial; SA: Salicylic acid; TCA: Trichloroacetic acid.

Risk of bias in included studies

The methodological quality of included RCTs was generally low-to-moderate, and in some cases very low. The risk of bias for each included study is shown in Figure 2, with the percentage of each risk of bias item across studies summarized in Figure 3.

Effects of interventions

Due to significant differences across studies with regard to interventions (different chemical peels and regimens), outcomes and follow-up durations, data from the different studies could not be combined for meta-analysis. In total, we identified eight different chemical peels and grouped the data into 11 comparisons.

Comparison 1: Trichloroacetic acid (TCA) peel versus salicylic acid (SA) peel

One RCT (20 participants, split-face comparison) compared 25% TCA (every two weeks, four sessions) to 30% SA (every two weeks, four sessions) for the treatment of mild-to-moderate acne vulgaris. Skin lesions significantly improved, from baseline, in both treatment groups, with no significant difference between TCA and SA with respect to the percentage of total improvement for all lesions (85% versus 95%; RR 0.89; 95% CI, 0.73-1.10), for non-inflammatory lesions (80% versus 70%; RR 1.14; 95% CI, 0.80-1.64) and for inflammatory lesions (80% versus 85%; RR 0.94; 95% CI, 0.71-1.25).⁸

Adverse events: No adverse event was identified for the SA peel. For the TCA peel, four patients (20%) reported hyperpigmentation, which lasted for 3 to 4 weeks.⁸

1
2
3 *Comparison 2: SA peel versus phototherapy*
4
5

6 One RCT (22 participants) compared 10% SA (every one week, 10 sessions) to
7 phototherapy (every one week, 10 sessions). Both interventions significantly
8 improved acne lesions, with no significant difference between the two interventions
9 with respect to the reduction in the number of comedones (MD, 2.00; 95% CI,
10 -3.67-7.67) and papules (MD, -1.00; 95% CI, -4.40-2.40). However, the SA peel did
11 not reduce the number of pustules to the same extent as phototherapy (MD, -7.00; 95%
12 CI, -10.84- -3.16).⁹
13
14
15
16
17
18
19
20
21
22

23 Adverse events: No information on adverse effects was reported.⁹
24
25

26 *Comparison 3: SA peel versus Jessner's solution (JS) peel*
27

28 Two RCTs compared SA to JS peels.^{10 11} Because of significant differences in the
29 treatment regimen, measured outcomes, and follow-up duration, data from these two
30 studies could not be combined for analysis.
31
32
33
34

35 One RCT (13 patients, split-face comparison) compared 30% SA (every two weeks,
36 three sessions) to JS (every two weeks, three sessions).¹⁰ The authors stated that SA
37 “seemed to be more effective than” JS for the treatment of non-inflammatory lesions.
38
39
40
41
42
43 However, relevant supporting data for this conclusion were not clearly described. As
44 well, the authors reported that both SA and JS were effective for reducing
45 inflammatory lesions; but without comparing the effects of SA and JS on this
46 outcome.
47
48
49
50
51

52 The other RCT (40 patients) also compared 30% SA (every two weeks, six sessions)
53 to JS (every two weeks, six sessions).¹¹ SA was superior to JS with respect to overall
54
55
56
57
58
59
60

percentage decrease in the mean number of comedones (53.4% and 26.3%, respectively, $p=0.001$), with equivalent outcomes for papules (71.0% and 61.5%, respectively, $p=0.870$) and pustules (70.3% and 76.7%, respectively, $p=0.570$). The proportional decrease in the mean Michaelsson acne score (MAS), before and after treatment, was greater for SA than JS (60.4% and 34.1%, respectively, $p=0.002$).

Adverse events: Initial burning sensations, post-peel erythema and mild scaling were common complaints that were comparable for the SA and JS groups.¹¹ One patient reported intense scaling on the side treated with SA.¹⁰ There was no report of hyperpigmentation.

Dayal et al. reported that SA and JS were both well-tolerated, although SA induced more burning and stinging sensation (65% and 45%, respectively; RR 2.27; 95% CI, 0.64-8.11; non-significant between-group difference).¹¹ On the other hand, post-peel erythema was less common in the SA group than JS group (20% and 30%, respectively; RR 0.58; 95% CI 0.14-2.50; non-significant between-group difference). Hyperpigmentation was rare in both groups (5% and 15%, respectively; RR 0.30; 95% CI, 0.30-3.15).

Comparison 4: SA plus mandelic acid (MA) peel versus glycolic acid (GA) peel

One RCT (40 patients) compared 20% SA plus 10% MA (every 2 weeks, six sessions) to 35% GA (every 2 weeks, 6 sessions).¹² The combination of SA and MA was superior to GA with respect to the percentage of improvement, from baseline, in comedones (90.2% and 35.9%, respectively, $p<0.05$), papules (81.7% and 77.8%, respectively, $p=0.006$), and pustules (85.4% and 75.7%, respectively, $p<0.001$), as

well as for the total acne score (85.3% and 68.5%, respectively, $p < 0.001$).

Adverse events: There was no significant difference between these two intervention groups in terms of burning or stinging sensation (20% and 10%, respectively; RR, 2.00; 95% CI, 0.41-9.71), skin dryness (15% and 10%, respectively; RR, 1.50; 95% CI, 0.28-8.04), and acne flare-up (10% each; RR, 1.00; 95% CI, 0.16-6.42). However, the combination of SA and MA, induced more visible desquamation than GA (80% and 40%, respectively; RR, 2.00; 95% CI, 1.12-3.57).

Comparison 5: GA peel versus amino fruit acid (AFA) peel

One RCT (30 patients, split-face comparison) compared GA (at concentrations of 20%, 35%, 50%, and 70%; every 2 weeks, 12 sessions) to AFA (at similar concentrations of 20%, 30%, 40%, 50%, and 60%; every 2 weeks, 12 sessions). Both peeling agents significantly improved acne lesions, with comparable effectiveness in reducing the number of non-inflammatory lesion counts (MD, 2.35; 95% CI, -18.66-23.36), the reduction of inflammatory lesions (MD, 0.20; 95% CI, -3.03-3.43), and patients' choice of future treatment (GA, 45.8%; AFA, 54.2%; RR, 0.85; 95% CI, 0.48-1.50).

Adverse events: All patients reported erythema at least once for both peels over the follow-up period. Edema was more common for GA than AFA (91.7% and 50%, respectively; RR, 1.83; 95% CI, 1.21-2.78). The incidence of frosting was comparable both GA and AFA peels (29.2% versus 16.7%, respectively; RR, 1.75; 95% CI, 0.59-5.21). Of note, all patients reported a level of discomfort with the GA peel that negatively affected daily life.

1
2
3 *Comparison 6: SA peel versus pyruvic acid (PA) peel*
4
5

6 One RCT (86 patients) compared 30% SA (every 2 weeks, five sessions) to 50% PA
7 (every 2 weeks, five sessions).¹³ The two peels had similar effects for reducing
8 comedones (MD, 7.45; 95% CI, -18.46-33.36), papules (MD, -0.20; 95% CI,
9 -5.36-4.96) and pustules (MD, -1.03; 95% CI, -2.01-0.05). Achievement of an
10 excellent or good improvement of all lesions was comparable for both SA and PA
11 peels (66.7% and 60%, respectively; RR, 1.11; 95% CI, 0.73-1.69).¹³
12
13

14 Adverse events: Burning sensation was very common (>85%) for both peels. The
15 incidence of scaling, erythema or itching was also reported to be comparable for both
16 peels (with no data presented). Hyperpigmentation was rare and comparable for the
17 SA and PA peels (11.1% and 8%, respectively; RR, 1.39; 95% CI, 0.25-7.64).
18
19
20
21
22
23
24
25
26
27
28
29

30 *Comparison 7: GA peel versus placebo*
31
32

33 One RCT (25 patients, split-face comparison) compared 40% GA (every 2 weeks, 5
34 sessions) to a placebo (every 2 weeks, 5 sessions).¹⁴ GA was significantly superior to
35 the placebo for reducing the number of non-inflammatory lesions (no data available,
36 p<0.01), inflammatory lesions (no data available, p<0.01) and total lesions (no data
37 available, p<0.01).¹⁴ Achievement of an excellent or good improvement of all lesions
38 was also superior for GA than the placebo (92% versus 40%, respectively; RR, 2.30;
39 95% CI, 1.40-3.77).
40
41
42
43
44
45
46
47
48
49

50 Adverse events: The authors reported that most patients suffered from “transient
51 post-treatment mild erythema that lasted a few minutes at most”, but no supporting
52 data was presented.¹⁴ Mild dryness was less common in the GA than placebo group
53
54
55
56
57
58
59
60

(28% and 100%, respectively; RR, 0.29; 95% CI, 0.16-0.54), with the incidence of scaling being comparable between the groups (16% and 12%, respectively; RR, 1.33; 95% CI, 0.33-5.38). A rate of flare-up of 12% was reported of GA, with no flare-up for the placebo, although this difference was not significant (RR, 7.00; 95% CI, 0.38-128.87).

Comparison 8: GA peel versus SA peel

One RCT (20 patients, split-face comparison) compared 30% GA (every 2 weeks, 6 sessions) to 30% SA (every 2 weeks, 6 sessions).¹⁹ Good or fair improvement in the total number of lesions at 1-month post-treatment was achieved with both GA and SA (94.1% each, RR, 1.00; 95% CI, 0.85-1.18). However, the mean number of all lesions was significantly higher on the GA-treated side than on the SA-treated side after a 2-month follow-up of no treatment (no data available, $p < 0.01$). In terms of the patients' self-assessment, 41% of patients preferred GA over SA; 35% preferring SA (RR, 1.17; 95% CI, 0.49-2.75).

Adverse events: The authors reported that both GA and SA were safe and well-tolerated, with no difference in the rate of adverse events between the two peels. The most common adverse events were scaling, peeling and erythema (no data available).

Comparison 9: GA peel versus JS peel

One RCT (26 patients, split-face comparison) compared 70% GA (every 2 weeks, 3 sessions) to JS (every 2 weeks, 3 sessions).²⁰ Both GA and JS had similar effects in

1
2
3
4 improving acne scores by ≥ 0.5 (50% each; RR, 1.00; 95% CI, 0.58-1.72).
5
6 Self-reported improvement was equivalent for GA and JS (30.7% and 30.7%,
7
8 respectively; RR, 1.00; 95% CI, 0.44-2.26), as was the choices for future treatment
9
10 (50% and 30.7%, respectively; RR, 1.63; 95% CI, 0.81-3.65).
11
12

13 Adverse events: Erythema was common for both peels (no data available). However,
14
15 JS induced scaling which negatively influenced patients' daily life (GA, 0%; JS, 36%;
16
17 RR, 0.05; 95% CI, 0-0.86). Two patients failed to tolerate the 70% GA treatment due
18
19 to the development of acute eczema, crusting and oozing.
20
21

22 23 *Comparison 10: TCA peel versus non-purpuric pulsed dye laser*

24
25
26 One RCT (45 patients) compared 25% TCA peel (every 2 weeks, 6 sessions) to
27
28 non-purpuric pulsed dye laser (every 2 weeks, 6 sessions).²¹ The mean acne severity
29
30 score was significantly improved, from baseline, for both TCA and laser therapy (MD
31
32 0.28; 95% CI, -0.33-0.89), with the clinical response being equivalent for both agents
33
34 (40% and 46.2%, respectively; RR, 0.87; 95% CI, 0.37-2.04). However, the mean
35
36 remission period after treatment was significantly shorter for TCA than that laser
37
38 therapy (MD -1.60 months, 95% CI -1.85 - -1.35).
39
40
41

42
43 Adverse events: The authors classified adverse events as follows: none; trace; mild;
44
45 moderate; and severe. No severe adverse events were reported. Two patients (13%) in
46
47 the TCA peel group and three (23.1%) in the laser therapy group reported moderate
48
49 adverse events (RR, 0.58; 95% CI, 0.11-2.94). Mild adverse events were reported in
50
51 six patients (40%) in the TCA peel group and five (38.5%) in the laser therapy group
52
53 (RR, 1.04; 95% CI, 0.41-2.62). Both treatments were deemed to be well-tolerated.
54
55
56

1
2
3 *Comparison 11: Lipohydroxy acid (LHA) peel versus SA peel*
4
5

6 One RCT (20 patients) compared LHA (5% or 10%, every 2 weeks, 6 sessions) to SA
7
8 (20% or 30%, every 2 weeks, 6 sessions).¹⁵ Both LHA and SA reduced the number of
9
10 non-inflammatory lesions (55.6% and 48.5%, respectively, p=0.878) and
11
12 inflammatory lesions (no data available, p=0.111).
13
14

15 Adverse events: Both LHA and SA peels were well-tolerated. The global tolerance for
16
17 the SA peel was better than that for the LHA peel when assessed by patients (no data
18
19 available, p=0.028), but with no difference when assessed by the investigator (no data
20
21 available, p=0.546).
22
23
24
25

26 **DISCUSSION**

27
28
29 Based on our analysis of the data presented in the 12 included RCTs, chemical peeling
30
31 offers an overall positive response for the treatment of acne vulgaris. The following
32
33 head-to-head comparisons demonstrated the equivalence of the following peels for the
34
35 treatment of acne vulgaris: TCA versus SA, GA versus AFA, SA versus PA, GA
36
37 versus SA, GA versus JS, and LHA versus SA. Moreover, the combination of SA and
38
39 MA provides a more effective peeling than GA. Furthermore, SA was found to be
40
41 more effective than JS for the treatment of comedones, but less effective than
42
43 phototherapy to treat pustules. The effectiveness of TCA is comparable to that of
44
45 pulsed dye laser therapy, but with laser providing a longer period of remission.
46
47
48
49

50 All chemical peels evaluated were well-tolerated with the most common adverse
51
52 events as follows: transient burning or sting sensation; postpeel erythema or scaling;
53
54
55
56

1
2
3 and topical edema or dryness. A few patients reported an acne flare-up with the
4
5 combination of SA and MA peel or with GA. Hyperpigmentation was a rare adverse
6
7 event reported in patients treated with TCA, SA and JS peels. Of note, this CT did not
8
9 have sufficient power to identify all adverse events, especially for rare adverse events,
10
11 due to limited sample size.²²
12
13

14
15 The information provided in our review may assist dermatologist in selecting most
16
17 appropriate chemical peels to treat acne vulgaris. However, our findings should be
18
19 considered with caution as included RCTs were conducted in different countries and
20
21 recruited individuals of different ethnicities. The choice of chemical peels should be
22
23 individualized, based on patient's skin type, history of acne or other skin diseases and
24
25 relevant treatments, and patient's expectations. For example, chemical peels,
26
27 especially medium or deep peels, are unsuitable for those with a Fitzpatrick skin type
28
29 V or VI, these peels may cause dyspigmentation and scarring in these patients.^{23 24} In
30
31 fact, most included studies recruited patients with a Fitzpatrick skin type I-IV,
32
33 although some studies did not report the skin type. In addition, most included studies
34
35 focused on mild-to-moderate acne.
36
37

38
39 There is currently no consensus regarding a standardized regimen for chemical
40
41 peeling, with the optimal concentration, treatment interval, and duration for different
42
43 chemical peels remaining unclear. Similarly, in our review, the regimen of chemical
44
45 peels varied significantly across studies. For example, the concentration of GA in
46
47 different RCTs varied from 10% to 70%, whereas the treatment durations varied from
48
49 six to 24 weeks. Studies are warranted to compare different regimens of the same
50
51
52
53
54
55
56
57

1
2
3
4 chemical peel in order to determine the optimal regimen for each peeling agent.

5
6 There is an emergent trend to using a combination of peeling agents, with the belief
7
8 that better clinical results can be achieved while reducing the risk of adverse events.³
9

10
11 As examples, Vitalize Peel contains both SA and lactic acid, with Micropeel Plus
12
13 containing SA and GA. include acne vulgaris.⁵ However, we failed to find any RCT
14
15 to confirm the efficacy of the premixed chemical peeling agents for acne. In the future,
16
17 more attention should be paid to these premixed formulating of chemical peels.
18

19
20 The limitations of our review need acknowledgement. First, all included studies were
21
22 of very low-to-moderate methodological quality, with small sample sizes, which
23
24 might induce bias, which we evaluated for each study. As an example, most of the
25
26 included RCTs did not describe the method of randomization. Adherence to the
27
28 recommendations from the Consolidated Standards of Reporting Trials (CONSORT)
29
30 Statement would be important to avoid incomplete and inadequate reporting and
31
32 improve the quality of the evidence.²⁵ Second, this review did not cover the effects of
33
34 chemical peeling for acne scarring, although chemical peels are used clinically for this
35
36 indication.²⁶ Lastly, as previously discussed, absence of standardization of peeling
37
38 regiment limits the translation of our findings to practice.
39

40
41 In conclusion, current evidence supports chemical peeling as a useful and
42
43 well-tolerated intervention for the treatment of mild-to-moderate acne vulgaris.
44
45 Commonly used chemical peels have similar effects. However, there is limited data
46
47 regarding premixed chemical peels for acne vulgaris. Well-designed and well-reported
48
49 RCTs are needed to provide high quality evidence to inform practice, particularly in
50
51
52
53
54
55
56

1
2
3 regard to optimal formulation and regiment of chemical peeling agents for various
4
5 ethnic populations and skin types.
6
7

8 9 **ACKNOWLEDGEMENT**

10
11
12 None.
13
14

15 16 **COMPETING INTERESTS**

17
18
19 All authors have not conflict of interest to declare.
20
21

22 23 **CONTRIBUTORS**

24
25
26 XC and LL designed the protocol. XC and MY searched the literature, extracted the
27
28 data, and analysed the data. XC, SW, MY and LL interpreted the data and revised the
29
30 manuscript.
31
32

33 34 **FUNDING**

35
36
37 This review was supported by a grant from the Sichuan Provincial Science and
38
39 Technology Department (Grant number: 2017JY0277).
40
41

42 43 **DISCLAIMER**

44
45
46 The funder had no role in study design, data collection, data analysis, data
47
48 interpretation or writing of the report.
49
50

51 52 **REFERENCES**

53
54
55 1. Sathish D, Shayeda, Rao YM. Acne and its treatment options: a review. *Curr*
56

- 1
2
3
4 *Drug Deliv* 2011;8(6):634-9.
- 5
6 2. Bhate K, Williams HC. Epidemiology of acne vulgaris. *Br J Dermatol*
7
8 2013;168(3):474-85. doi: 10.1111/bjd.12149
9
- 10
11 3. Kontochristopoulos G, Platsidaki E. Chemical peels in active acne and acne
12
13 scars. *Clinics in Dermatology* 2017;35(2):179-82.
14
- 15
16 4. Salam A, Dadzie OE, Galadari H. Chemical peeling in ethnic skin: an update.
17
18 *British Journal of Dermatology* 2013;169 Suppl 3:82-90.
19
- 20
21 5. Jackson A. Chemical peels. *Facial Plast Surg* 2014;30(1):26-34. doi:
22
23 10.1055/s-0033-1364220
24
- 25
26 6. Dreno B, Fischer TC, Perosino E, et al. Expert opinion: efficacy of superficial
27
28 chemical peels in active acne management--what can we learn from the
29
30 literature today? Evidence-based recommendations. *Journal of the*
31
32 *European Academy of Dermatology & Venereology*
33
34 2011;25(6):695-704.
35
- 36
37 7. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the
38
39 management of acne vulgaris. *J Am Acad Dermatol* 2016;74(5):945-73
40
41 e33. doi: 10.1016/j.jaad.2015.12.037
42
43
44
- 45
46 8. Abdel Meguid AM, Elaziz Ahmed Attallah DA, Omar H. Trichloroacetic Acid
47
48 Versus Salicylic Acid in the Treatment of Acne Vulgaris in Dark-Skinned
49
50 Patients. *Dermatologic Surgery* 2015;41(12):1398-404.
51
- 52
53 9. Alba MN, Gerenutti M, Yoshida VM, et al. Clinical comparison of salicylic
54
55 acid peel and LED-Laser phototherapy for the treatment of Acne
56
57

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- vulgaris in teenagers. *Journal of Cosmetic & Laser Therapy* 2017;19(1):49-53.
10. Bae BG, Park CO, Shin H, et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. *Dermatologic Surgery* 2013;39(2):248-53.
11. Dayal S, Amrani A, Sahu P, et al. Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. *J Cosmet Dermatol* 2017;16(1):43-51. doi: 10.1111/jocd.12266
12. ElRefaei AM, Abdel Salam HA, Sorour NE. Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. *Journal of the Egyptian Women's Dermatologic Society* 2015;12(3):196-202.
13. Jaffary F FGSSHSM. Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. *Journal of research in medical sciences* 2016;21(2)
14. Kaminaka C, Uede M, Matsunaka H, et al. Clinical evaluation of glycolic acid chemical peeling in patients with acne vulgaris: a randomized, double-blind, placebo-controlled, split-face comparative study. *Dermatologic Surgery* 2014;40(3):314-22.
15. Levesque A, Hamzavi I, Seite S, et al. Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. *Journal*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- of Cosmetic Dermatology* 2011;10(3):174-8.
16. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535. doi: 10.1136/bmj.b2535
17. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011 [Available from: www.handbook.cochrane.org].
18. Ilknur T, Demirtasoglu M, Bicak MU, et al. Glycolic acid peels versus amino fruit acid peels for acne. *Journal of Cosmetic & Laser Therapy* 2010;12(5):242-5.
19. Kessler E, Flanagan K, Chia C, et al. Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. *Dermatologic Surgery* 2008;34(1):45-50; discussion 51.
20. Kim SW, Moon SE, Kim JA, et al. Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. *Dermatologic Surgery* 1999;25(4):270-3.
21. Leheta TM. Role of the 585-nm pulsed dye laser in the treatment of acne in comparison with other topical therapeutic modalities. *Journal of Cosmetic & Laser Therapy* 2009;11(2):118-24.
22. Wahab IA, Pratt NL, Kalisch LM, et al. The detection of adverse events in

randomized clinical trials: can we really say new medicines are safe?

Current drug safety 2013;8(2):104-13. [published Online First: 2013/05/30]

23. Been MJ, Mangat DS. Laser and face peel procedures in non-Caucasians.

Facial Plastic Surgery Clinics of North America 2014;22(3):447-52.

24. Handog EB, Datuin MS, Singzon IA. Chemical peels for acne and acne

scars in asians: evidence based review. *Journal of Cutaneous & Aesthetic Surgery* 2012;5(4):239-46.

25. Boutron I, Altman DG, Moher D, et al. CONSORT Statement for

Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Ann Intern Med* 2017;167(1):40-47. doi: 10.7326/M17-0046

26. Abdel Hay R, Shalaby K, Zaher H, et al. Interventions for acne scars.

Cochrane Database of Systematic Reviews 2016(pagination)

FIGURE LEGEND

Figure 1. The Preferred Reporting Items for Systematic Reviews (PRISMA) diagram of the study flow.

Figure 2. Risk of bias summary for each study.

Figure 3. Risk of bias summary graph of all included studies.

1
2
3 **SUPPLEMENTARY FILES**
4

5
6 Supplementary Table 1. The search strategies for MEDLINE, EMBASE and
7
8 CENTRAL via OvidSP.
9

10
11 Supplementary Table 2. Reasons for the exclusion of studies
12
13

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. The Preferred Reporting Items for Systematic Reviews (PRISMA) diagram of the study flow.

176x297mm (300 x 300 DPI)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Abdel 2015	●	●	●	+	+	+	?
Alba 2017	?	?	●	+	+	+	?
Bae 2013	?	?	●	+	+	+	?
Dayal 2017	+	?	?	+	?	+	?
EIRefaei 2015	?	+	●	●	+	+	?
Ilknur 2010	?	?	?	+	●	+	?
Jaffary 2016	?	?	?	?	●	+	?
Kaminaka 2014	?	?	+	+	+	+	?
Kessler 2008	?	?	?	+	●	+	?
Kim 1999	+	?	●	?	?	+	?
Leheta 2009	?	?	●	?	+	+	?
Levesque 2011	+	+	?	+	●	+	+
Majid 2013	+	?	?	+	+	+	?

Figure 2. Risk of bias summary for each study.

138x297mm (300 x 300 DPI)




Figure 3. Risk of bias summary graph of all included studies.

209x87mm (300 x 300 DPI)

Peer review only

Supplementary Table 1. The search strategies for searching MEDLINE, EMBASE, and CENTRAL via OvidSP

No.	Searches
1	(chemical adj (peel* or resurface*).ab,kw,ti. ((hydroxy or glycolic or lactic or malic or citric or tartaric or salicylic or trichloroacetic or pyruvic or lipohydroxy or salicylic-mandelic or "amino fruit") adj acid*).ab,kw,ti.
2	adj acid*).ab,kw,ti.
3	("Jessner's solution" or "Jessner's solutions").ab,kw,ti.
4	(resorcinol* or phenol*).ab,kw,ti.
5	acne.ab,kw,ti.
6	exp *Acne Vulgaris/
7	1 or 2 or 3 or 4
8	5 or 6
9	7 and 8
10	remove duplicates from 9

Supplementary Table 2. Characteristics of excluded studies

Studies	Reason for exclusion
Garg 2009 ¹	This study is not an RCT.
Kim 2015 ²	This RCT compared alpha hydroxy acids plus an additional physical treatment with alpha hydroxy acids alone.
Lee 2006 ³	This study is not an RCT.
Lekakh 2015 ⁴	This study compared chemical peel and the combination of laser and chemical peel.
Nofal 2014 ⁵	This study appears to be not an RCT because of the significant difference between the method section and the abstract about the randomization. And there is no reply from the authors to clarify this inconsistency.
Sharad 2011 ⁶	This study is not an RCT
Wang 1997 ⁷	This study is not an RCT

RCT: randomized controlled trial.

References of the excluded studies:

1. Garg VK, Sinha S , Sarkar R. Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. *Dermatologic Surgery* 2009;35:59-65.
2. Kim SJ, Baek JH, Koh JS, Bae MI, Lee SJ , Shin MK. The effect of physically applied

1
2
3
4 alpha hydroxyl acids on the skin pore and comedone. International Journal of
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

alpha hydroxyl acids on the skin pore and comedone. International Journal of
Cosmetic Science 2015;37:519-25.

3. Lee SH, Huh CH, Park KC , Youn SW. Effects of repetitive superficial chemical
peels on facial sebum secretion in acne patients. Journal of the European
Academy of Dermatology & Venereology 2006;20:964-8.

4. Lekakh O, Mahoney AM, Novice K, Kamalpour J, Sadeghian A, Mondo D et al.
Treatment of Acne Vulgaris With Salicylic Acid Chemical Peel and Pulsed Dye Laser:
A Split Face, Rater-Blinded, Randomized Controlled Trial. Journal of Lasers in
Medical Sciences 2015;6:167-70.

5. Nofal E, Helmy A, Nofal A, Alakad R , Nasr M. Platelet-rich plasma versus CROSS
technique with 100% trichloroacetic acid versus combined skin needling and
platelet rich plasma in the treatment of atrophic acne scars: a comparative study.
Dermatologic Surgery 2014;40:864-73.

6. Sharad J. Combination of microneedling and glycolic acid peels for the
treatment of acne scars in dark skin. Journal of Cosmetic Dermatology
2011;10:317-23.

7. Wang CM, Huang CL, Hu CT , Chan HL. The effect of glycolic acid on the
treatment of acne in Asian skin. Dermatologic Surgery 1997;23:23-9.



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5-6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supplementary table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	-
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Not necessary

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	-
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Not necessary
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Fig 2 and 3
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	12-19
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Meta-analysis is not possible to be performed.
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	-
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Not necessary
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	20-21
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	22

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only

BMJ Open

Chemical peels for acne vulgaris: a systematic review of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019607.R1
Article Type:	Research
Date Submitted by the Author:	14-Feb-2018
Complete List of Authors:	Chen, Xiaomei; Sichuan University West China Hospital, Department of Dermatology & Venereology Wang, Sheng; Sichuan University West China Hospital, Department of Dermatology & Venereology Yang, Ming; The Center of Gerontology and Geriatrics; Li, Li; Sichuan University West China Hospital, Department of Dermatology & Venereology
Primary Subject Heading:	Dermatology
Secondary Subject Heading:	Evidence based practice, Infectious diseases
Keywords:	chemical peeling, acne vulgaris, systematic review, treatment, comedone, papule

SCHOLARONE™
Manuscripts

Title Page

Title

Chemical peels for acne vulgaris: a systematic review of randomized controlled trials

Authors

Xiaomei Chen M.D., Sheng Wang M.D., Ming Yang M.D., Li Li M.D.

Affiliations and locations of all authors

Xiaomei Chen: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Sheng Wang: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Ming Yang: The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China

Li Li: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Corresponding author

Li Li, M.D.: Department of Dermatology & Venereology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China.

Telephone: +86 28 85423315; Fax: +86 28 85423315; Email:

hxskincos2017@qq.com

Word counts

Manuscript: 4338 words

Abstract

Objective: We evaluated current evidence from randomized controlled trials (RCTs) regarding the effectiveness of chemical peeling for treating acne vulgaris.

Methods: Standard Cochrane methodological procedures were used. We searched MEDLINE, Cochrane Central Register of Controlled Trials, and EMBASE via OvidSP through April 2017. Reviewers independently assessed eligibility and risk of bias, and extracted data.

Results: Twelve RCTs (387 participants) were included. Effectiveness was equivalent for trichloroacetic acid versus salicylic acid (SA), glycolic acid (GA) versus amino fruit acid, SA versus pyruvic acid, GA versus SA, GA versus Jessner's solution (JS), and lipohydroxy acid versus SA. Combination of SA and mandelic acid peels was superior to GA peeling. GA peeling was superior to placebo. SA peeling may be superior to JS peeling for comedones, but it is less effective than phototherapy for pustules. The methodological quality of all RCTs was very low to moderate.

Conclusions: Commonly used chemical peels have similar effectiveness for mild to moderate acne vulgaris and are well tolerated. Further evaluation is needed to identify optimal regimens.

Keywords: chemical peeling; acne vulgaris; systematic review; treatment; comedone; papule; pustule

Strengths and limitations of this study

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis protocols (PRISMA) protocols and Cochrane methodological procedures. We could not perform a meta-analysis due to the significant heterogeneity across the RCTs.

ARTICLE SUMMARY

- Chemical peeling is widely used for acne vulgaris.
- Chemical peeling is a useful and well-tolerated method for improving acne lesions. Commonly used chemical peels have similar effects, but data regarding premixed peeling agents are limited.
- Premixed peels and optimal regimens need further evaluation.

INTRODUCTION

Acne is one of the most common skin disorders and is prevalent in most ethnic populations.¹ Acne affects 85% to 90% of adolescents, and may persist into adulthood.^{2 3} Acne vulgaris can negatively affect an individual's appearance and self-esteem, thereby causing anxiety, depression, poor quality of life, and even suicidal thought.^{1 2} Skin lesions of acne vulgaris are classified as either non-inflammatory (comedones) or inflammatory (papules, pustules, nodules, and cysts). Acne vulgaris treatments include systemic therapies (oral antibiotics and

retinoid), topical therapies (benzoyl peroxide) and physical modalities (laser therapy and chemical peeling).

Chemical peeling is a skin resurfacing procedure commonly used for facial rejuvenation and esthetics.³ It causes a manageable injury to the skin, thus resulting in subsequent regeneration of a new epidermal layer of the dermal tissues.⁴ The injury depth is determined by the concentration of acid used, and by the type of vehicle, buffering and contact time with the skin. Therefore, chemical peels are, therefore, classified as superficial (destroying the epidermis), moderate (destroying the papillary dermis and upper reticular dermis) or deep (destroying part or all of the mid-reticular dermis).⁵ Although often used to treat acne, chemical peeling is also widely used as a cosmetic treatment for melasma, photoaging and lentigines.⁵ Superficial peels are generally used for acne vulgaris, whereas deep peels are used to treat acne scars. Commonly used agents for chemical peels are summarized in Table 1.

Table 1. Commonly used chemical peels for acne vulgaris

Chemical peels	Abbreviations
α -Hydroxy acid	AHA
Amino fruit acid	AFA
Glycolic acid	GA
Mandelic acid	MA
Tartaric acid	TA
β -Hydroxy acid	BHA
Salicylic acid	SA
Azelaic acid	AZA
Lipohydroxy acid	LHA
Jessner's solution*	JS
Pyruvic acid	PA
Retinoic acid	RA
Trichloroacetic acid	TCA

*Jessner's solution is a premixed formula containing 14% salicylic acid, 14% lactic acid, and 14% resorcinol.

1
2
3
4 The exact pathogenesis of acne vulgaris remains unclear. However, the proliferation
5
6 of *Propionibacterium acnes*, increased levels of inflammatory cytokines and sebum
7
8 production, and follicular hyperkeratinization are involved.³ Chemical peels have
9
10 antibacterial, anti-inflammatory, keratolytic, and comedolytic effects, and they can
11
12 reduce sebum production. Therefore, chemical peels have been widely used to treat
13
14 acne vulgaris, either as a supplementary therapy or as a maintenance therapy.^{3 5 6}

15
16
17
18 Despite their wide application, evidence regarding the effectiveness of chemical peels
19
20 to treat acne vulgaris is limited. A 2016 recommendation for the treatment of acne
21
22 vulgaris indicated that chemical peels were supported by level B evidence, namely
23
24 “inconsistent or limited-quality patient-oriented evidence”.⁷ This recommendation
25
26 was based on the evaluation of two trials^{8 9} and a previously published guideline⁶,
27
28 and it only included research from the PubMed and the Cochrane Library databases,
29
30 from May 2006 to September 2014. Therefore, potential evidence from other
31
32 important medical databases was possibly omitted. In addition, new randomized
33
34 controlled trials (RCTs) were performed after September 2014.⁹⁻¹⁶ Therefore, we
35
36 performed a systematic review to summarize current evidence regarding the
37
38 effectiveness of chemical peeling for acne vulgaris and to evaluate the validity of the
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
aforementioned recommendations.

58 59 60 **METHODS**

61 62 63 **Systematic search of the literature**

64
65
66
67
68
69
70
This review was performed according to the guidelines for the Preferred Reporting

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Items for Systematic Reviews and Meta-Analysis protocols (PRISMA)¹⁷ and the Standard Cochrane methodological procedures.¹⁸ The following databases were searched up to April 25, 2017, using the strategy summarized in Supplementary Table 1: MEDLINE via OvidSP (from 1946); EMBASE via OvidSP (from 1974); and the Cochrane Central Register of Controlled Trials (CENTRAL) 2017, Issue 4.

We also hand-searched all bibliographies of the included and excluded studies and previous systematic reviews to identify further relevant trials.

Inclusion and exclusion criteria

We included all RCTs addressing any chemical peel (compared to placebo or any other treatment) for the treatment of acne vulgaris in any study population. Studies that recruited patients with sequelae of acne, such as post-inflammatory dyschromia or scarring, evaluated the combined effects of chemical agents and other therapies, such as laser therapy, were quasi-RCTs, and were not published in English were excluded.

Selection of studies

Two authors (X.C. and M.Y.) independently reviewed the titles and abstracts identified from the searches and selected possible relevant studies. After reviewing the full text of these studies, the two authors independently decided on which studies to include and excluded and record reasons for exclusion. Any discrepancy in selection was resolved through discussion.

Data extraction

Two authors (X.C. and M.Y.) independently extracted the information from the included studies using the “characteristics of included studies form” recommended by the Cochrane Handbook for Systematic Review of Interventions.¹⁸ Another author (WS) verified and compared the data extraction forms.

Assessment of the risk of bias in included trials

Two authors (X.C. and M.Y.) independently evaluated the risk of bias of the included trials by using the methods recommended by the Cochrane Handbook for Systematic Review of Interventions.¹⁸ Discrepancies were resolved through discussion. The Cochrane risk of bias for each included trial was classified as low, high, or unclear.

Measure of treatment effects

Dichotomous outcomes (such as the percentage of meaningful improvement in the total number of lesions) were reported, when possible, as risk ratios (RRs), with the associated 95% confidence intervals (CIs). Continuous outcomes (such as the number of inflammatory lesions) were reported as the mean difference (MD), with the associated 95% CI.

Heterogeneity and data synthesis

Significant clinical heterogeneity across the included RCTs was identified. Specifically, the skin type of participants, interventions (e.g., the type, concentration,

1
2
3 and regimen of chemical peeling agents), and outcome measurements were all
4 significantly different across the included RCTs. Therefore, it was not possible to
5
6 merge data from different trials to perform a meta-analysis.
7
8
9

10 11 **RESULTS**

12 13 14 **Description of studies**

15
16 After removing duplicates, we identified 605 articles during the initial search. Of
17 these, 586 were discarded after screening the titles and abstracts, leaving 19 studies
18 for full review. Another seven were excluded after this review. Reasons for exclusion
19 are summarized in Supplementary Table 2. Our final analysis included 12 RCTs,
20 providing data from 387 participants. The PRISMA diagram for study selection is
21 presented in Figure 1. Relevant characteristics of the included RCTs are summarized
22 in Table 2.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Summary of relevant characteristics of included studies

Studies	Publication year	Study design	Country	Sample size	Women (%)	Fitzpatrick skin type	Acne severity	Interventions	Main outcomes	Follow-up (weeks)
Abdel et al. ¹⁰	2015	Single-center, double-blind, split-face RCT	Egypt	20	85	III, IV, V	Mild to moderate	25% TCA versus 30% SA	<ul style="list-style-type: none"> ✧ Percentage of total/ good/ fair/ poor improvement in total lesions ✧ Percentage of total/ good/ fair/ poor improvement in non-inflammatory lesions ✧ Percentage of total/ good/ fair/ poor improvement in inflammatory lesions ✧ Reduction of lesion counts ✧ Adverse events 	10
Alba et al. ¹¹	2017	Single-center, single-blind RCT	Brazil	22	41	II, III, IV, VI	Mild to moderate	10% SA versus phototherapy	<ul style="list-style-type: none"> ✧ Comedone counts ✧ Papule counts ✧ Pustule counts 	10
Bae et al. ¹²	2013	Single-center, single-blind, split-face RCT	Korea	13	0	III or IV	Mild to moderate	30% SA versus JS	<ul style="list-style-type: none"> ✧ Number of non-inflammatory lesions ✧ Number of inflammatory lesions ✧ Self-reported good/ moderate/ mild/ no improvement in all lesions ✧ Adverse events 	8
Dayal et al. ¹³	2017	Single-center, single-blind RCT	India	40	35	N/A	Mild to moderate	30% SA versus JS	<ul style="list-style-type: none"> ✧ Comedone counts ✧ Overall percentage decrease in mean comedone counts ✧ Papule counts ✧ Overall percentage decrease in mean papule counts ✧ Pustule counts ✧ Overall percentage decrease in mean pustules 	12

Study ID	Year	Design	Country	n1	n2	Interventions	Severity	Comparison	Outcomes	Count
EIRefaei et al. ¹⁴	2015	Single-center, open-label RCT	Egypt	40	80	I, II, III, IV	Mild to very severe	20% SA + 10% MA versus 35% GA	counts ✧ MAS ✧ Percentage decrease in mean MAS ✧ Percentage of good/ fair/ poor response ✧ Adverse events ✧ Comedone counts ✧ Papule counts ✧ Pustule counts ✧ Percentage of improvement in comedones/ papules/ pustules/ the total acne score ✧ Adverse events	20
Ilknur et al. ⁸	2010	Single-center, single-blind, split-face RCT	Turkey	30	N/A	II, III	Mild to moderate	GA versus AFA	✧ Non-inflammatory lesion counts ✧ Inflammatory lesion counts ✧ Patients' choice for the future treatment ✧ Adverse events	24
Jaffary et al. ¹⁵	2016	Multi-center, single-blind RCT	Iran	86	92	N/A	Mild to moderate	30% SA versus 50% PA	✧ Comedone counts ✧ Papule counts ✧ Pustule counts ✧ Percentage of excellent/ good/ fair/ poor improvement of all lesions ✧ Acne severity index (ASI) ✧ Percentage of patient satisfaction ✧ Adverse events	8
Kaminaka et al. ¹⁶	2014	Single-center, double-blind, split-face RCT	Japan	25	64	N/A	Moderate to severe	40% GA versus Placebo	✧ Non-inflammatory lesion counts ✧ Inflammatory lesion counts ✧ Total lesion counts ✧ Percentage of excellent/ good/ fair/ bad improvement in all lesions ✧ Bioengineering measurements ✧ Adverse events	10
Kessler et al. ¹⁹	2008	Single-center, double-blind, split-face RCT	United States	20	65	N/A	Mild to moderate	30% GA versus 30% SA	✧ Mean number of all lesions ✧ Reduction of all lesions ✧ Percentage of good/ fair/ poor improvement in all lesions	20

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Kim et al. ²⁰	1999	Single-center, single-blind, split-face RCT	Korea	26	84.6	III, IV	Mild to moderate	to	70%	GA	<ul style="list-style-type: none"> ✧ Self-reported overall improvement ✧ Adverse events ✧ Percentage of patients' who achieved improvement in acne scores of 0.5 or more ✧ Self-reported overall improvement ✧ Patients' choice for the future treatment ✧ Adverse events 	8
Leheta et al. ²¹	2009	Single-center, single-blind, RCT	Egypt	45	N/A	II, III, IV	Mild to moderate	to	20%	TCA	<ul style="list-style-type: none"> ✧ Acne severity score ✧ Mean remission period ✧ Percentage of marked/ moderate response ✧ Self-reported cost-effectiveness ratio ✧ Adverse events 	48
Levesque et al. ⁹	2011	Single-center, open-label, split-face RCT	United States	20	95	N/A	N/A			LHA (5% or 10%) versus SA (20% or 30%)	<ul style="list-style-type: none"> ✧ Reduction of non-inflammatory lesions ✧ Inflammatory lesion counts ✧ Global acne assessment ✧ Adverse events 	14

AFA: Amino fruit acid; AZA: Azelaic acid; GA: Glycolic acid; JS: Jessner's solution; LHA: Lipohydroxy acid; MA: Mandelic acid; N/A: not available; PA: Pyruvic acid; PDL: pulsed dye laser; RCT: Randomized controlled trial; SA: Salicylic acid; TCA: Trichloroacetic acid.

Risk of bias in included studies

The methodological quality of included RCTs was generally low to moderate; however, in some cases, it was very low. The risk of bias in each included study is shown in Figure 2, with the percentage of each risk of bias item across studies summarized in Figure 3.

Effects of interventions

Due to significant differences across studies with regard to interventions (different chemical peels and regimens), outcomes and follow-up durations, data from the different studies could not be combined to perform a meta-analysis. We identified a total of eight different chemical peels and grouped the data into 11 comparisons.

Comparison 1: Trichloroacetic acid peel versus salicylic acid peel

One RCT (20 participants, split-face comparison) compared 25% trichloroacetic acid TCA (every 2 weeks, 4 sessions) to 30% salicylic acid (SA; every 2 weeks, 4 sessions) for the treatment of mild-to-moderate acne vulgaris. Skin lesions significantly improved, from baseline, in both treatment groups, with no significant difference between TCA and SA regarding the percentage of total improvement for all lesions (85% versus 95%; RR 0.89; 95% CI, 0.73-1.10), for non-inflammatory lesions (80% versus 70%; RR 1.14; 95% CI, 0.80-1.64) and for inflammatory lesions (80% versus 85%; RR 0.94; 95% CI, 0.71-1.25).¹⁰

Adverse events

1
2
3
4 No adverse event was identified for the SA peel. For the TCA peel, four patients (20%)
5
6 reported hyperpigmentation that lasted for 3 to 4 weeks.¹⁰
7

8
9 *Comparison 2: SA peel versus phototherapy*

10
11 One RCT (22 participants) compared 10% SA (once every week, 10 sessions) to
12
13 phototherapy (once every week, 10 sessions). Both interventions significantly
14
15 improved acne lesions, with no significant difference between the two interventions
16
17 regarding the reduction in the number of comedones (MD, 2.00; 95% CI, -3.67 to 7.67)
18
19 and papules (MD, -1.00; 95% CI, -4.40 to 2.40). However, the SA peel did not reduce
20
21 the number of pustules to the same extent as phototherapy (MD, -7.00; 95% CI,
22
23 -10.84 to -3.16).¹¹
24
25
26
27

28
29 *Adverse events*

30
31 No information regarding adverse effects was reported.¹¹
32

33
34 *Comparison 3: SA peel versus Jessner's solution peel*

35
36 Two RCTs compared SA to Jessner's solution (JS) peels.^{12 13} Because of significant
37
38 differences in the treatment regimen, measured outcomes, and follow-up duration,
39
40 data from these two studies could not be combined for analysis.
41
42

43
44 One RCT (13 patients, split-face comparison) compared 30% SA (every 2 weeks, 3
45
46 sessions) to JS (every 2 weeks, 3 sessions).¹² The authors stated that SA "seemed to
47
48 be more effective than" JS for the treatment of non-inflammatory lesions. However,
49
50 relevant data supporting this conclusion were not clearly described. Furthermore, the
51
52 authors reported that both SA and JS were effective for reducing inflammatory lesions;
53
54
55
56

1
2
3
4 however, they did not compare the effects of SA and JS on this outcome.

5
6 Another RCT (40 patients) also compared 30% SA (every 2 weeks, 6 sessions) to JS
7
8 (every 2 weeks, 6 sessions).¹³ SA was superior to JS regarding overall percentage
9
10 decrease in the mean number of comedones (53.4% and 26.3%, respectively, p=0.001),
11
12 with equivalent outcomes for papules (71.0% and 61.5%, respectively, p=0.870) and
13
14 pustules (70.3% and 76.7%, respectively, p=0.570). The proportional decreases in the
15
16 mean Michaelsson acne score (MAS), before and after treatment, were greater for SA
17
18 than for JS (60.4% and 34.1%, respectively, p=0.002).
19
20
21
22

23 Adverse events

24
25 Initial burning sensations, post-peel erythema and mild scaling were common
26
27 symptoms that were comparable for the SA and JS groups.¹³ One patient reported
28
29 intense scaling on the side that was treated with SA.¹² There was no report of
30
31 hyperpigmentation.
32
33

34
35 Dayal et al. reported that SA and JS were both well-tolerated, although SA induced
36
37 more burning and stinging sensation (65% and 45%, respectively; RR 2.27; 95% CI,
38
39 0.64-8.11; non-significant between-group difference).¹³ However, post-peel erythema
40
41 was less common in the SA group than in the JS group (20% and 30%, respectively;
42
43 RR 0.58; 95% CI 0.14-2.50; non-significant between-group difference).
44
45
46
47 Hyperpigmentation was rare in both groups (5% and 15%, respectively; RR 0.30; 95%
48
49 CI, 0.30-3.15).
50
51

52 *Comparison 4: SA plus mandelic acid peel versus glycolic acid peel*

53
54
55 One RCT (40 patients) compared 20% SA plus 10% mandelic acid (MA; every 2
56
57

1
2
3
4 weeks, 6 sessions) to 35% glycolic acid (GA; every 2 weeks, 6 sessions).¹⁴ The
5
6 combination of SA and MA was superior to GA regarding the percentage of
7
8 improvement, from baseline, in comedones (90.2% and 35.9%, respectively, $p<0.05$),
9
10 papules (81.7% and 77.8%, respectively, $p=0.006$), and pustules (85.4% and 75.7%,
11
12 respectively, $p<0.001$), as well as in the total acne score (85.3% and 68.5%,
13
14 respectively, $p<0.001$).

15 16 17 18 Adverse events

19
20 There was no significant difference between these two intervention groups in terms of
21
22 burning or stinging sensations (20% and 10%, respectively; RR, 2.00; 95% CI,
23
24 0.41-9.71), skin dryness (15% and 10%, respectively; RR, 1.50; 95% CI, 0.28-8.04),
25
26 and acne flare-up (10% each; RR, 1.00; 95% CI, 0.16-6.42). However, the
27
28 combination of SA and MA, induced more visible desquamation than GA (80% and
29
30 40%, respectively; RR, 2.00; 95% CI, 1.12-3.57).

31 32 33 34 35 36 37 *Comparison 5: GA peel versus amino fruit acid peel*

38
39 One RCT (30 patients, split-face comparison) compared GA (at concentrations of
40
41 20%, 35%, 50%, and 70%; every 2 weeks, 12 sessions) to amino fruit acid (AFA) (at
42
43 similar concentrations of 20%, 30%, 40%, 50%, and 60%; every 2 weeks, 12
44
45 sessions).⁸ Both peeling agents significantly improved acne lesions and had
46
47 comparable effectiveness in reducing the number of non-inflammatory lesion counts
48
49 (MD, 2.35; 95% CI, -18.66 to 23.36), the reduction of inflammatory lesions (MD,
50
51 0.20; 95% CI, -3.03 to 3.43), and patient's choice of future treatment (GA, 45.8%;
52
53 AFA, 54.2%; RR, 0.85; 95% CI, 0.48-1.50).

1
2
3
4 Adverse events: All patients reported erythema at least once for both peels during the
5
6 follow-up period. Edema was more common for GA than for AFA (91.7% and 50%,
7
8 respectively; RR, 1.83; 95% CI, 1.21-2.78).⁸ The incidence of frosting was
9
10 comparable for both GA and AFA peels (29.2% versus 16.7%, respectively; RR, 1.75;
11
12 95% CI, 0.59-5.21). Of note, all patients reported discomfort that negatively affected
13
14 daily life with the GA peel.
15
16

17
18 *Comparison 6: SA peel versus pyruvic acid peel*
19

20
21 One RCT (86 patients) compared 30% SA (every 2 weeks, five sessions) to 50%
22
23 pyruvic acid (PA; every 2 weeks, 5 sessions).¹⁵ The two peels had similar effects for
24
25 reducing comedones (MD, 7.45; 95% CI, -18.46 to 33.36), papules (MD, -0.20; 95%
26
27 CI, -5.36 to 4.96) and pustules (MD, -1.03; 95% CI, -2.01 to 0.05). Achievement of an
28
29 excellent or good improvement in all lesions was comparable for both SA and PA
30
31 peels (66.7% and 60%, respectively; RR, 1.11; 95% CI, 0.73-1.69).¹⁵
32
33

34
35
36 Adverse events

37
38 Burning sensations were very common (>85%) for both peels. The incidences of
39
40 scaling, erythema and itching were also reported to be comparable for both peels
41
42 (with no data presented). Hyperpigmentation was rare and comparable for the SA and
43
44 PA peels (11.1% and 8%, respectively; RR, 1.39; 95% CI, 0.25-7.64).
45
46
47

48
49 *Comparison 7: GA peel versus placebo*
50

51
52 One RCT (25 patients, split-face comparison) compared 40% GA (every 2 weeks, 5
53
54 sessions) to a placebo (every 2 weeks, 5 sessions).¹⁶ GA was significantly superior to
55
56

1
2
3
4 the placebo for reducing the number of non-inflammatory lesions (no data available,
5
6 $p < 0.01$), inflammatory lesions (no data available, $p < 0.01$) and total lesions (no data
7
8 available, $p < 0.01$).¹⁶ Achievement of excellent or good improvement in all lesions
9
10 was also superior for GA than for placebo (92% versus 40%, respectively; RR, 2.30;
11
12 95% CI, 1.40-3.77).

13 14 15 Adverse events

16
17 The authors reported that most patients experienced “transient post-treatment mild
18
19 erythema that lasted a few minutes at most”, but no supporting data were presented.¹⁶
20
21 Mild dryness was less common in the GA group than in the placebo group (28% and
22
23 100%, respectively; RR, 0.29; 95% CI, 0.16-0.54); however, with the incidence of
24
25 scaling was comparable between the groups (16% and 12%, respectively; RR, 1.33;
26
27 95% CI, 0.33-5.38). A flare-up rate of 12% was reported for GA, with no flare-up
28
29 reported for the placebo, although this difference was not significant (RR, 7.00; 95%
30
31 CI, 0.38-128.87).

32 33 34 35 36 37 38 *Comparison 8: GA peel versus SA peel*

39
40 One RCT (20 patients, split-face comparison) compared 30% GA (every 2 weeks, 6
41
42 sessions) to 30% SA (every 2 weeks, 6 sessions).¹⁹ Good or fair improvement in the
43
44 total number of lesions at 1-month post-treatment was achieved with both GA and SA
45
46 (94.1% each, RR, 1.00; 95% CI, 0.85-1.18). However, the mean number of all lesions
47
48 was significantly higher on the GA-treated side than on the SA-treated side after a
49
50 2-month follow-up with no treatment (no data available, $p < 0.01$). In terms of the
51
52 patients’ self-assessments, 41% of patients preferred GA over SA and 35% preferred
53
54
55
56
57
58
59
60

SA (RR, 1.17; 95% CI, 0.49-2.75).

Adverse events

The authors reported that both GA and SA were safe and well-tolerated, with no difference in adverse events rates between the two peels. The most common adverse events were scaling, peeling and erythema (no data available).

Comparison 9: GA peel versus JS peel

One RCT (26 patients, split-face comparison) compared 70% GA (every 2 weeks, 3 sessions) to JS (every 2 weeks, 3 sessions).²⁰ Both GA and JS had similar effects and improved acne scores by ≥ 0.5 (50% each; RR, 1.00; 95% CI, 0.58-1.72). Self-reported improvements were equivalent for GA and JS (30.7% and 30.7%, respectively; RR, 1.00; 95% CI, 0.44-2.26), as were the choices for future treatment (50% and 30.7%, respectively; RR, 1.63; 95% CI, 0.81-3.65).

Adverse events

Erythema was common for both peels (no data available). However, JS induced scaling that negatively influenced patients' daily life (GA, 0%; JS, 36%; RR, 0.05; 95% CI, 0-0.86). Two patients could not tolerate the 70% GA treatment due to the development of acute eczema, crusting and oozing.

Comparison 10: TCA peel versus non-purpuric pulsed dye laser

One RCT (45 patients) compared 25% TCA peel (every 2 weeks, 6 sessions) to non-purpuric pulsed dye laser (every 2 weeks, 6 sessions).²¹ The mean acne severity score was significantly improved, from baseline, for both TCA and laser therapy (MD

0.28; 95% CI, -0.33 to 0.89); the clinical response was equivalent for both agents (40% and 46.2%, respectively; RR, 0.87; 95% CI, 0.37-2.04). However, the mean remission period after treatment was significantly shorter for TCA than for laser therapy (MD -1.60 months, 95% CI -1.85 to -1.35).

Adverse events

The authors classified adverse events as follows: none; trace; mild; moderate; and severe. No severe adverse events were reported. Two patients (13%) in the TCA peel group and three (23.1%) in the laser therapy group reported moderate adverse events (RR, 0.58; 95% CI, 0.11-2.94). Mild adverse events were reported for six patients (40%) in the TCA peel group and five (38.5%) in the laser therapy group (RR, 1.04; 95% CI, 0.41-2.62). Both treatments were considered to be well-tolerated.

Comparison 11: Lipohydroxy acid peel versus SA peel

One RCT (20 patients) compared lipohydroxy acid (LHA; 5% or 10%, every 2 weeks, 6 sessions) to SA (20% or 30%, every 2 weeks, 6 sessions).⁹ Both LHA and SA reduced the number of non-inflammatory lesions (55.6% and 48.5%, respectively, $p=0.878$) and inflammatory lesions (no data available, $p=0.111$).

Adverse events

Both LHA and SA peels were well-tolerated. The global tolerance for the SA peel was better than that for the LHA peel when assessed by patients (no data available, $p=0.028$), but there was no difference when assessed by the investigator (no data available, $p=0.546$).

DISCUSSION

To the best of our knowledge, this is the first systematic review addressing chemical peels for treating acne vulgaris. Based on our analysis of the data presented in the 12 included RCTs, chemical peeling is an overall positive method of treating acne vulgaris. The following comparisons demonstrated the equivalence of peels for the treatment of acne vulgaris: TCA versus SA, GA versus AFA, SA versus PA, GA versus SA, GA versus JS, and LHA versus SA. Moreover, the combination of SA and MA provides a more effective peeling than GA. Furthermore, SA was found to be more effective than JS for the treatment of comedones, but less effective than phototherapy to treat pustules. The effectiveness of TCA is comparable to that of pulsed dye laser therapy, but the laser provided a longer period of remission.

All chemical peels evaluated were well-tolerated. The most common adverse events were: transient burning or sting sensations; post-peel erythema or scaling; and topical edema or dryness. A few patients reported acne flare-ups with the combination of SA and MA peel and with GA. Hyperpigmentation was a rare adverse event reported by patients treated with TCA, SA, and JS peels. Of note, this RCT did not have sufficient power to identify all adverse events, especially for rare adverse events, due to the limited sample size.²²

The information provided in our review may assist dermatologists with selecting the most appropriate chemical peels to treat acne vulgaris. However, our findings should be considered with caution because the included RCTs were performed in different countries and recruited individuals of different ethnicities. The choice of chemical

1
2
3
4 peels should be individualized, based on patient's skin type, history of acne or other
5
6 skin diseases and relevant treatments, and patient's expectations. For example,
7
8 chemical peels, especially medium or deep peels, are unsuitable for those with a
9
10 Fitzpatrick skin type V or VI, because these peels may cause dyspigmentation and
11
12 scarring in these patients.^{23 24} In fact, most included studies recruited patients with a
13
14 Fitzpatrick skin type I through IV, although some studies did not report the skin type.
15
16 In addition, most included studies focused on mild to moderate acne.
17
18

19
20 There is currently no consensus regarding the standardized regimen for chemical
21
22 peeling, because the optimal concentration, treatment interval, and duration for
23
24 different chemical peels remain unclear. In our review, the regimen of chemical peels
25
26 varied significantly across studies. For example, the concentration of GA used in
27
28 different RCTs varied from 10% to 70%, and the treatment durations varied from 6 to
29
30 24 weeks. Studies are warranted to compare different regimens of the same chemical
31
32 peel to determine the optimal regimen for each peeling agent.
33
34

35
36 There is an emerging trend of using a combination of peeling agents because of the
37
38 belief that better clinical results can be achieved while reducing the risk of adverse
39
40 events.³ As examples, Vitalize Peel[®] contains both SA and lactic acid, with Micropeel
41
42 Plus[®] contains SA and GA for treating acne vulgaris.⁵ However, we could not find
43
44 any RCT to confirm the efficacy of the premixed chemical peeling agents for acne. In
45
46 the future, more attention should be focused on these premixed formulating of
47
48 chemical peels.
49
50

51
52 In this review, we surprisingly found that only one RCT¹⁶ compared a chemical
53
54

1
2
3 peeling agent (GA) to placebo for acne vulgaris. However, more than 10 chemical
4
5 peeling agents have been applied in the real world. Further well-designed RCTs are
6
7
8 needed to compare other chemical peels to placebo. A network meta-analysis based on
9
10 these RCTs should provide more valuable and robust evidence for clinical practice.
11
12 Additionally, the outcome measurements were significantly different across the
13
14 included RCTs, which made it difficult to compare or merge the results of different
15
16 studies. Therefore, we suggest that the future version of the guideline of care for the
17
18 management of acne vulgaris should make recommendations regarding the standard
19
20 of outcome measurements. Our review has some limitations. First, all included studies
21
22 were of very low-to-moderate methodological quality, with small sample sizes, which
23
24 might have introduced bias. However, we evaluated for bias in each study. For
25
26 example, most of the included RCTs did not describe the method of randomization. It
27
28 is important to adhere to the recommendations of the Consolidated Standards of
29
30 Reporting Trials (CONSORT) statement to avoid incomplete and inadequate reporting
31
32 and to improve the quality of the evidence.²⁵ Second, this review did not investigate
33
34 the effects of chemical peeling for acne scarring, although chemical peels are used
35
36 clinically for this indication.²⁶ Finally, as previously discussed, the absence of a
37
38 standardized peeling regimen limits the translation of our findings to clinical practice.
39
40
41
42
43
44
45
46
47

48 CONCLUSION

51 Implication for practice

52 Current evidence supports chemical peeling as a useful and well-tolerated intervention
53
54
55
56

1
2
3 for the treatment of mild-to-moderate acne vulgaris. Commonly used chemical peels
4
5
6 have similar effects. However, there are limited data regarding premixed chemical
7
8
9 peels for acne vulgaris.

10 11 **Implications for research**

12
13
14
15 Well-designed and well-reported RCTs are needed to provide high quality evidence to
16
17 inform practice, particularly regarding the optimal formulation and regiment for
18
19 chemical peeling agents. Comparisons with placebo or each other should be
20
21 performed for various ethnic populations and skin types. In addition, standard
22
23 outcome measurements for the management of acne vulgaris are needed.
24
25
26

27 28 **ACKNOWLEDGEMENT**

29
30
31 None.

32 33 34 **COMPETING INTERESTS**

35
36
37 All authors have not conflict of interest to declare.

38 39 40 **CONTRIBUTORS**

41
42
43
44 XC and LL designed the protocol. XC and MY searched the literature, extracted the
45
46 data, and analysed the data. XC, SW, MY and LL interpreted the data and revised the
47
48 manuscript.
49
50
51
52
53
54
55
56

FUNDING

This review was supported by a grant from the Sichuan Provincial Science and Technology Department (Grant number: 2017JY0277).

DISCLAIMER

The funder had no role in study design, data collection, data analysis, data interpretation or writing of the report.

DATA SHARING STATEMENT

No additional data are available.

REFERENCES

1. Sathish D, Shayeda, Rao YM. Acne and its treatment options: a review. *Curr Drug Deliv* 2011;8(6):634-9.
2. Bhate K, Williams HC. Epidemiology of acne vulgaris. *Br J Dermatol* 2013;168(3):474-85. doi: 10.1111/bjd.12149
3. Kontochristopoulos G, Platsidaki E. Chemical peels in active acne and acne scars. *Clinics in Dermatology* 2017;35(2):179-82.
4. Salam A, Dadzie OE, Galadari H. Chemical peeling in ethnic skin: an update. *British Journal of Dermatology* 2013;169 Suppl 3:82-90.
5. Jackson A. Chemical peels. *Facial Plast Surg* 2014;30(1):26-34. doi: 10.1055/s-0033-1364220

- 1
2
3
4 6. Dreno B, Fischer TC, Perosino E, et al. Expert opinion: efficacy of superficial
5
6 chemical peels in active acne management--what can we learn from the
7
8 literature today? Evidence-based recommendations. *Journal of the*
9
10 *European Academy of Dermatology & Venereology*
11
12 2011;25(6):695-704.
13
14
15
16 7. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the
17
18 management of acne vulgaris. *J Am Acad Dermatol* 2016;74(5):945-73
19
20 e33. doi: 10.1016/j.jaad.2015.12.037
21
22
23 8. Ilknur T, Demirtasoglu M, Bicak MU, et al. Glycolic acid peels versus amino
24
25 fruit acid peels for acne. *Journal of Cosmetic & Laser Therapy*
26
27 2010;12(5):242-5.
28
29
30 9. Levesque A, Hamzavi I, Seite S, et al. Randomized trial comparing a
31
32 chemical peel containing a lipophilic hydroxy acid derivative of salicylic
33
34 acid with a salicylic acid peel in subjects with comedonal acne. *Journal*
35
36 *of Cosmetic Dermatology* 2011;10(3):174-8.
37
38
39
40 10. Abdel Meguid AM, Elaziz Ahmed Attallah DA, Omar H. Trichloroacetic Acid
41
42 Versus Salicylic Acid in the Treatment of Acne Vulgaris in Dark-Skinned
43
44 Patients. *Dermatologic Surgery* 2015;41(12):1398-404.
45
46
47
48 11. Alba MN, Gerenutti M, Yoshida VM, et al. Clinical comparison of salicylic
49
50 acid peel and LED-Laser phototherapy for the treatment of Acne
51
52 vulgaris in teenagers. *Journal of Cosmetic & Laser Therapy*
53
54 2017;19(1):49-53.
55
56

- 1
2
3
4 12. Bae BG, Park CO, Shin H, et al. Salicylic acid peels versus Jessner's
5
6 solution for acne vulgaris: a comparative study. *Dermatologic Surgery*
7
8 2013;39(2):248-53.
9
- 10
11 13. Dayal S, Amrani A, Sahu P, et al. Jessner's solution vs. 30% salicylic acid
12
13 peels: a comparative study of the efficacy and safety in
14
15 mild-to-moderate acne vulgaris. *J Cosmet Dermatol* 2017;16(1):43-51.
16
17 doi: 10.1111/jocd.12266
18
- 19
20 14. ElRefaei AM, Abdel Salam HA, Sorour NE. Salicylic-mandelic acid versus
21
22 glycolic acid peels in Egyptian patients with acne vulgaris. *Journal of the*
23
24 *Egyptian Women's Dermatologic Society* 2015;12(3):196-202.
25
- 26
27 15. Jaffary F FGSSHSM. Comparison the effectiveness of pyruvic acid 50%
28
29 and salicylic acid 30% in the treatment of acne. *Journal of research in*
30
31 *medical sciences* 2016;21(2)
32
- 33
34 16. Kaminaka C, Uede M, Matsunaka H, et al. Clinical evaluation of glycolic
35
36 acid chemical peeling in patients with acne vulgaris: a randomized,
37
38 double-blind, placebo-controlled, split-face comparative study.
39
40 *Dermatologic Surgery* 2014;40(3):314-22.
41
42
- 43
44 17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for
45
46 systematic reviews and meta-analyses: the PRISMA statement. *BMJ*
47
48 2009;339:b2535. doi: 10.1136/bmj.b2535
49
- 50
51 18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of
52
53 Interventions Version 5.1.0 [updated March 2011]: The Cochrane
54
55
56
57
58
59

- Collaboration; 2011 [Available from: www.handbook.cochrane.org].
19. Kessler E, Flanagan K, Chia C, et al. Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. *Dermatologic Surgery* 2008;34(1):45-50; discussion 51.
20. Kim SW, Moon SE, Kim JA, et al. Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. *Dermatologic Surgery* 1999;25(4):270-3.
21. Leheta TM. Role of the 585-nm pulsed dye laser in the treatment of acne in comparison with other topical therapeutic modalities. *Journal of Cosmetic & Laser Therapy* 2009;11(2):118-24.
22. Wahab IA, Pratt NL, Kalisch LM, et al. The detection of adverse events in randomized clinical trials: can we really say new medicines are safe? *Current drug safety* 2013;8(2):104-13. [published Online First: 2013/05/30]
23. Been MJ, Mangat DS. Laser and face peel procedures in non-Caucasians. *Facial Plastic Surgery Clinics of North America* 2014;22(3):447-52.
24. Handog EB, Datuin MS, Singzon IA. Chemical peels for acne and acne scars in asians: evidence based review. *Journal of Cutaneous & Aesthetic Surgery* 2012;5(4):239-46.
25. Boutron I, Altman DG, Moher D, et al. CONSORT Statement for

1
2
3
4 Randomized Trials of Nonpharmacologic Treatments: A 2017 Update
5
6 and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Ann*
7
8 *Intern Med* 2017;167(1):40-47. doi: 10.7326/M17-0046
9

10
11 26. Abdel Hay R, Shalaby K, Zaher H, et al. Interventions for acne scars.
12
13 *Cochrane Database of Systematic Reviews* 2016(pagination)
14
15

16 17 **FIGURE LEGEND**

18
19
20 Figure 1. Preferred Reporting Items for Systematic Reviews (PRISMA) diagram of
21
22 the study flow.
23

24
25 Figure 2. Risk of bias summary for each study.
26

27
28 Figure 3. Risk of bias summary graph for all included studies.
29
30

31 32 **SUPPLEMENTARY FILES**

33
34
35
36 Supplementary Table 1. The search strategies for MEDLINE, EMBASE and
37
38 CENTRAL via OvidSP.
39

40
41 Supplementary Table 2. Reasons for study exclusion
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Preferred Reporting Items for Systematic Reviews (PRISMA) diagram of the study flow.

213x260mm (300 x 300 DPI)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Abdel 2015	●	●	●	+	+	+	?
Alba 2017	?	?	●	+	+	+	?
Bae 2013	?	?	●	+	+	+	?
Dayal 2017	+	?	?	+	?	+	?
EIRefaei 2015	?	+	●	●	+	+	?
Ilknur 2010	?	?	?	+	●	+	?
Jaffary 2016	?	?	?	?	●	+	?
Kaminaka 2014	?	?	+	+	+	+	?
Kessler 2008	?	?	?	+	●	+	?
Kim 1999	+	?	●	?	?	+	?
Leheta 2009	?	?	●	?	+	+	?
Levesque 2011	+	+	?	+	●	+	+
Majid 2013	+	?	?	+	+	+	?

Figure 2. Risk of bias summary for each study.

138x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Risk of bias summary graph of all included studies.

209x87mm (300 x 300 DPI)

Peer review only

Supplementary Table 1. Search strategies for searching MEDLINE, EMBASE, and CENTRAL via OvidSP

No.	Searches
1	(chemical adj (peel* or resurface*).ab,kw,ti. ((hydroxy or glycolic or lactic or malic or citric or tartaric or salicylic or trichloroacetic or pyruvic or lipohydroxy or salicylic-mandelic or "amino fruit") adj acid*).ab,kw,ti.
2	adj acid*).ab,kw,ti.
3	("Jessner's solution" or "Jessner's solutions").ab,kw,ti.
4	(resorcinol* or phenol*).ab,kw,ti.
5	acne.ab,kw,ti.
6	exp *Acne Vulgaris/
7	1 or 2 or 3 or 4
8	5 or 6
9	7 and 8
10	remove duplicates from 9

Supplementary Table 2. Reasons for study exclusion

Studies	Reason for exclusion
Garg 2009 ¹	This study is not an RCT.
Kim 2015 ²	This RCT compared alpha hydroxy acids plus an additional physical treatment with alpha hydroxy acids alone.
Lee 2006 ³	This study is not an RCT.
Lekakh 2015 ⁴	This study compared chemical peel and the combination of laser and chemical peel.
Nofal 2014 ⁵	This study appears to be not an RCT because of the significant difference between the method section and the abstract about the randomization. And there is no reply from the authors to clarify this inconsistency.
Sharad 2011 ⁶	This study is not an RCT
Wang 1997 ⁷	This study is not an RCT

RCT: randomized controlled trial.

References of the excluded studies:

1. Garg VK, Sinha S , Sarkar R. Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. *Dermatologic Surgery* 2009;35:59-65.
2. Kim SJ, Baek JH, Koh JS, Bae MI, Lee SJ , Shin MK. The effect of physically applied

1
2
3
4 alpha hydroxyl acids on the skin pore and comedone. International Journal of
5
6 Cosmetic Science 2015;37:519-25.

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3. Lee SH, Huh CH, Park KC , Youn SW. Effects of repetitive superficial chemical peels on facial sebum secretion in acne patients. Journal of the European Academy of Dermatology & Venereology 2006;20:964-8.

4. Lekakh O, Mahoney AM, Novice K, Kamalpour J, Sadeghian A, Mondo D et al. Treatment of Acne Vulgaris With Salicylic Acid Chemical Peel and Pulsed Dye Laser: A Split Face, Rater-Blinded, Randomized Controlled Trial. Journal of Lasers in Medical Sciences 2015;6:167-70.

5. Nofal E, Helmy A, Nofal A, Alakad R , Nasr M. Platelet-rich plasma versus CROSS technique with 100% trichloroacetic acid versus combined skin needling and platelet rich plasma in the treatment of atrophic acne scars: a comparative study. Dermatologic Surgery 2014;40:864-73.

6. Sharad J. Combination of microneedling and glycolic acid peels for the treatment of acne scars in dark skin. Journal of Cosmetic Dermatology 2011;10:317-23.

7. Wang CM, Huang CL, Hu CT , Chan HL. The effect of glycolic acid on the treatment of acne in Asian skin. Dermatologic Surgery 1997;23:23-9.



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5-6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supplementary table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	-
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Not necessary

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	-
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Not necessary
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Fig 2 and 3
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	12-19
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Meta-analysis is not possible to be performed.
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	-
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Not necessary
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	20-21
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	22

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only

BMJ Open

Chemical peels for acne vulgaris: a systematic review of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019607.R2
Article Type:	Research
Date Submitted by the Author:	14-Mar-2018
Complete List of Authors:	Chen, Xiaomei; Sichuan University West China Hospital, Department of Dermatology & Venereology Wang, Sheng; Sichuan University West China Hospital, Department of Dermatology & Venereology Yang, Ming; The Center of Gerontology and Geriatrics; Li, Li; Sichuan University West China Hospital, Department of Dermatology & Venereology
Primary Subject Heading:	Dermatology
Secondary Subject Heading:	Evidence based practice, Infectious diseases
Keywords:	chemical peeling, acne vulgaris, systematic review, treatment, comedone, papule

SCHOLARONE™
Manuscripts

Title Page

Title

Chemical peels for acne vulgaris: a systematic review of randomized controlled trials

Authors

Xiaomei Chen M.D., Sheng Wang M.D., Ming Yang M.D., Li Li M.D.

Affiliations and locations of all authors

Xiaomei Chen: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Sheng Wang: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Ming Yang: The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China

Li Li: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China

Corresponding author

Li Li, M.D.: Department of Dermatology & Venereology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China.

Telephone: +86 28 85423315; Fax: +86 28 85423315; Email:

hxskincos2017@qq.com

Word counts

Manuscript: 4437 words

Abstract

Objective: We evaluated current evidence from randomized controlled trials (RCTs) regarding the effectiveness of chemical peeling for treating acne vulgaris.

Methods: Standard Cochrane methodological procedures were used. We searched MEDLINE, Cochrane Central Register of Controlled Trials, and EMBASE via OvidSP through April 2017. Reviewers independently assessed eligibility, risk of bias, and extracted data.

Results: Twelve RCTs (387 participants) were included. Effectiveness was not significantly different: trichloroacetic acid versus salicylic acid (SA) (percentage of total improvement: relative risk [RR] 0.89; 95% confidence interval [CI], 0.73-1.10), glycolic acid (GA) versus amino fruit acid (the reduction of inflammatory lesions: mean difference [MD], 0.20; 95% CI, -3.03 to 3.43), SA versus pyruvic acid (excellent or good improvement: RR, 1.11; 95% CI, 0.73-1.69), GA versus SA (good or fair improvement: RR, 1.00; 95% CI, 0.85-1.18), GA versus Jessner's solution (JS) (self-reported improvements: RR, 1.00; 95% CI, 0.44-2.26), and lipohydroxy acid versus SA (reduction of noninflammatory lesions: 55.6% vs. 48.5%, $p=0.878$).

1
2
3
4 Combined SA and mandelic acid peeling was superior to GA peeling (percentage of
5
6 improvement in total acne score: 85.3% vs. 68.5%, $p<0.001$). GA peeling was
7
8 superior to placebo (excellent or good improvement: RR, 2.30; 95% CI, 1.40-3.77).
9
10 SA peeling may be superior to JS peeling for comedones (reduction of comedones:
11
12 53.4% vs. 26.3%, $p=0.001$) but less effective than phototherapy for pustules (number
13
14 of pustules: MD, -7.00; 95% CI, -10.84 to -3.16).
15
16

17
18 **Limitations:** The methodological quality of the included RCTs was very low to
19
20 moderate. Meta-analysis was not possible due to the significant clinical heterogeneity
21
22 across studies.
23
24

25
26 **Conclusion:** Commonly used chemical peels appear to be similarly effective for
27
28 mild-to-moderate acne vulgaris and well tolerated. However, based on current limited
29
30 evidence, a robust conclusion cannot be drawn regarding any definitive superiority or
31
32 equality among the currently used chemical peels. Well-designed RCTs are needed to
33
34 identify optimal regimens.
35
36

37
38 **Keywords:** chemical peeling; acne vulgaris; systematic review; treatment; comedone;
39
40 papule; pustule
41
42

43 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

44

- 45
- 46 ● This review followed the Preferred Reporting Items for Systematic Reviews and
47 Meta-Analysis protocols (PRISMA) protocols and Cochrane methodological
48 procedures.
- 49
- 50
- 51 ● Twelve RCTs with 387 participants were included.
- 52
- 53 ● The methodological quality of the included RCTs was very low to moderate.
- 54
- 55 ● A meta-analysis cannot be performed due to the significant heterogeneity across
56

1
2
3 the RCTs.
4
5

6 INTRODUCTION 7

8
9 Acne is one of the most common skin disorders and is prevalent in most ethnic
10 populations.¹ Acne affects 85% to 90% of adolescents, and may persist into
11 adulthood.^{2 3} Acne vulgaris can negatively affect an individual's appearance and
12 self-esteem, thereby causing anxiety, depression, poor quality of life, and even
13 suicidal thought.^{1 2} Skin lesions of acne vulgaris are classified as either
14 noninflammatory (comedones) or inflammatory (papules, pustules, nodules, and
15 cysts). Acne vulgaris treatments include systemic therapies (oral antibiotics and
16 retinoid), topical therapies (benzoyl peroxide) and physical modalities (laser therapy
17 and chemical peeling).
18
19

20
21 Chemical peeling is a skin resurfacing procedure commonly used for facial
22 rejuvenation and esthetics.³ It causes a manageable injury to the skin, thus resulting in
23 subsequent regeneration of a new epidermal layer of the dermal tissues.⁴ The injury
24 depth is determined by the concentration of acid used, and by the type of vehicle,
25 buffering, and duration of skin contact. Therefore, chemical peels are classified as
26 superficial (destroying the epidermis), moderate (destroying the papillary dermis and
27 upper reticular dermis), or deep (destroying part or all of the mid-reticular dermis).⁵
28
29 Although often used to treat acne, chemical peeling is also widely used as a cosmetic
30 treatment for melasma, photoaging, and lentigines.⁵ Superficial peels are generally
31 used for acne vulgaris, whereas deep peels are used to treat acne scars. Commonly
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

used agents for chemical peels are summarized in Table 1.

Table 1. The abbreviations of commonly used chemical peels for acne vulgaris⁴⁻⁹

Chemical peels	Abbreviations
α-Hydroxy acid	AHA
Amino fruit acid	AFA
Glycolic acid	GA
Mandelic acid	MA
Tartaric acid	TA
β-Hydroxy acid	BHA
Salicylic acid	SA
Azelaic acid	AZA
Lipohydroxy acid	LHA
Jessner's solution*	JS
Pyruvic acid	PA
Retinoic acid	RA
Trichloroacetic acid	TCA

*Jessner's solution is a premixed formula containing 14% salicylic acid, 14% lactic acid, and 14% resorcinol.

The exact pathogenesis of acne vulgaris remains unclear. However, the proliferation of *Propionibacterium acnes*, increased levels of inflammatory cytokines and sebum production, and follicular hyperkeratinization are involved.³ Chemical peels have antibacterial, anti-inflammatory, keratolytic, and comedolytic effects, and they can reduce sebum production. Therefore, chemical peels have been widely used to treat acne vulgaris, either as a supplementary therapy or as a maintenance therapy.^{3 5 8}

Despite their wide application, evidence regarding the effectiveness of chemical peels in the treatment of acne vulgaris is limited. A 2016 recommendation for the treatment of acne vulgaris indicated that chemical peels were supported by level B evidence, namely, "inconsistent or limited-quality patient-oriented evidence".¹⁰ This

1
2
3 recommendation was based on the evaluation of two trials^{11 12} and a previously
4 published guideline⁸, and it only included research from the PubMed and the
5
6 Cochrane Library databases, from May 2006 to September 2014. Therefore, potential
7
8 evidence from other important medical databases was possibly omitted. In addition,
9
10 new randomized controlled trials (RCTs) were performed after September 2014.¹²⁻¹⁹
11
12 Thus, we performed a systematic review to summarize current evidence regarding the
13
14 effectiveness of chemical peeling for acne vulgaris and to evaluate the validity of the
15
16 aforementioned recommendations.
17
18
19
20
21
22
23

24 **METHODS**

25 **Systematic search of the literature**

26
27 This review was performed according to the guidelines for the Preferred Reporting
28
29 Items for Systematic Reviews and Meta-Analysis protocols (PRISMA)²⁰ and the
30
31 Standard Cochrane methodological procedures.²¹ The following databases were
32
33 searched until April 25, 2017, using the strategy summarized in Supplementary Table
34
35 1: MEDLINE via OvidSP (from 1946), EMBASE via OvidSP (from 1974), and the
36
37 Cochrane Central Register of Controlled Trials (CENTRAL) 2017, Issue 4.
38
39

40 We also hand-searched all bibliographies of the included and excluded studies and
41
42 previous systematic reviews to identify further relevant trials.
43
44

45 **Inclusion and exclusion criteria**

46 We included all RCTs addressing any chemical peel (compared to placebo or any
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 other treatment) for the treatment of acne vulgaris in any study population. Studies
4 that recruited patients with sequelae of acne, such as post-inflammatory dyschromia
5 or scarring; evaluated the combined effects of chemical agents and other therapies,
6 such as laser therapy; were quasi-RCTs; and were not published in English were
7 excluded.
8
9
10
11
12
13
14
15

16 **Selection of studies**

17
18
19 Two authors (X.C. and M.Y.) independently reviewed the titles and abstracts
20 identified from the searches and selected possible relevant studies. After reviewing the
21 full text of these studies, the two authors independently decided on which studies to
22 include and exclude and documented the reasons for exclusion. Any discrepancy in
23 the selection was resolved through discussion.
24
25
26
27
28
29
30
31
32

33 **Data extraction**

34
35
36 Two authors (X.C. and M.Y.) independently extracted the information from the
37 included studies using the “characteristics of included studies form” recommended by
38 the Cochrane Handbook for Systematic Review of Interventions.²¹ Another author
39 (W.S.) verified and compared the data extraction forms.
40
41
42
43
44
45
46

47 **Assessment of the risk of bias in included trials**

48
49
50 Two authors (X.C. and M.Y.) independently evaluated the risk of bias in the included
51 trials using the methods recommended by the Cochrane Handbook for Systematic
52 Review of Interventions.²¹ Discrepancies were resolved through discussion. The
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cochrane risk of bias for each included trial was classified as low, high, or unclear.

Measure of treatment effects

Dichotomous outcomes (such as the percentage of meaningful improvement in the total number of lesions) were reported, when possible, as risk ratios (RRs), with the associated 95% confidence intervals (CIs). Continuous outcomes (such as the number of inflammatory lesions) were reported as the mean difference (MD), with the associated 95% CI.

Heterogeneity and data synthesis

Significant clinical heterogeneity across the included RCTs was identified. Specifically, the skin type of participants, interventions (e.g., the type, concentration, and regimen of chemical peeling agents), and outcome measurements were all significantly different across the included RCTs. Therefore, it was not possible to merge data from different trials to perform a meta-analysis.

Patient and public involvement

Patients and public were not involved.

RESULTS

Description of studies

After removing duplicates, we identified 605 articles during the initial search. Of these, 586 were discarded after screening the titles and abstracts, leaving 19 studies

1
2
3 for full review. Another seven of the 19 studies were excluded after this review. The
4
5
6 reasons for exclusion are summarized in Supplementary Table 2. Our final analysis
7
8 included 12 RCTs, providing data from 387 participants. The PRISMA diagram for
9
10
11 study selection is presented in Figure 1. Relevant characteristics of the included RCTs
12
13 are summarized in Table 2.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2. Summary of relevant characteristics of included studies

Studies	Publication year	Study design	Country	Sample size	Men (%)	Fitzpatrick skin type	Acne severity	Interventions	Main outcomes	Follow-up (weeks)
Abdel et al. ¹³	2015	Single-center, double-blind, split-face RCT	Egypt	20	85	III, IV, V	Mild to moderate	25% TCA versus 30% SA (in hydroethanolic vehicle)	<ul style="list-style-type: none"> ✧ Percentage of total/ good/ fair/ poor improvement in total lesions ✧ Percentage of total/ good/ fair/ poor improvement in noninflammatory lesions ✧ Percentage of total/ good/ fair/ poor improvement in inflammatory lesions ✧ Reduction of lesion counts ✧ Adverse events 	10
Alba et al. ¹⁴	2017	Single-center, single-blind RCT	Brazil	22	41	II, III, IV, VI	Mild to moderate	10% SA (in cream-gel) versus phototherapy	<ul style="list-style-type: none"> ✧ Comedone counts ✧ Papule counts ✧ Pustule counts 	10
Bae et al. ¹⁵	2013	Single-center, single-blind, split-face RCT	Korea	13	0	III or IV	Mild to moderate	30% SA versus JS	<ul style="list-style-type: none"> ✧ Number of noninflammatory lesions ✧ Number of inflammatory lesions ✧ Self-reported good/ moderate/ mild/ no improvement in all lesions ✧ Adverse events 	8
Dayal et al. ¹⁶	2017	Single-center, single-blind RCT	India	40	35	N/A	Mild to moderate	30% SA versus JS	<ul style="list-style-type: none"> ✧ Comedone counts ✧ Overall percentage decrease in mean comedone counts ✧ Papule counts ✧ Overall percentage decrease in mean papule counts ✧ Pustule counts 	12

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

EI Refaie al. ¹⁷	et al.	2015	Single-center, open-label RCT	Egypt	40	80	I, II, III, IV	Mild to very severe	20% SA + 10% MA (in ethyl alcohol vehicle) versus 35% GA (in distilled water)	<ul style="list-style-type: none"> ✧ Overall percentage decrease in mean pustule counts ✧ MAS ✧ Percentage decrease in mean MAS ✧ Percentage of good/ fair/ poor response ✧ Adverse events ✧ Comedone counts ✧ Papule counts ✧ Pustule counts ✧ Percentage of improvement in comedones/ papules/ pustules/ the total acne score ✧ Adverse events 	20
Ilknur et al. ¹¹		2010	Single-center, single-blind, split-face RCT	Turkey	30	N/A	II, III	Mild to moderate	GA (from 20% to 70%) versus AFA (from 20% to 60%)	<ul style="list-style-type: none"> ✧ Noninflammatory lesion counts ✧ Inflammatory lesion counts ✧ Patients' choice for future treatment ✧ Adverse events 	24
Jaffary et al. ¹⁸		2016	Multi-center, single-blind RCT	Iran	86	92	N/A	Mild to moderate	30% SA (in alcohol vehicle) versus 50% PA (in hydro	<ul style="list-style-type: none"> ✧ Comedone counts ✧ Papule counts ✧ Pustule counts ✧ Percentage of excellent/ good/ fair/ poor improvement of all lesions ✧ Acne severity index (ASI) ✧ Percentage of patient satisfaction ✧ Adverse events 	8

1												
2												
3												
4												
5												
6												
7												
8												
9	Kaminaka et al. ¹⁹	2014	Single-center, double-blind, split-face RCT	Japan	25	64	N/A	Moderate to severe	alcoholic vehicle) 40% GA versus Placebo (hydrochloric acid in polyethylene glycol vehicle)	◇ Noninflammatory lesion counts ◇ Inflammatory lesion counts ◇ Total lesion counts ◇ Percentage of excellent/ good/ fair/ bad improvement in all lesions ◇ Bioengineering measurements ◇ Adverse events	10	
10												
11												
12												
13												
14												
15												
16												
17												
18												
19	Kessler et al. ²²	2008	Single-center, double-blind, split-face RCT	United States	20	65	N/A	Mild to moderate	30% GA versus 30% SA	◇ Mean number of all lesions ◇ Reduction of all lesions ◇ Percentage of good/ fair/ poor improvement in all lesions ◇ Self-reported overall improvement ◇ Adverse events	20	
20												
21												
22												
23												
24												
25	Kim et al. ²³	1999	Single-center, single-blind, split-face RCT	Korea	26	84.6	III, IV	Mild to moderate	70% GA versus JS (resorcinol, salicylic acid, lactic acid in ethanol)	◇ Percentage of patients who achieved improvement in acne scores of 0.5 or more ◇ Self-reported overall improvement ◇ Patients' choice for future treatment ◇ Adverse events	8	
26												
27												
28												
29												
30												
31												
32												
33												
34	Leheta et al. ²⁴	2009	Single-center, single-blind, RCT	Egypt	45	N/A	II, III, IV	Mild to moderate	20% TCA versus PDL	◇ Acne severity score ◇ Mean remission period ◇ Percentage of marked/ moderate response ◇ Self-reported cost-effectiveness ratio ◇ Adverse events	48	
35												
36												
37												
38												
39												
40												
41												
42												
43												
44												
45												
46												
47												

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Levesque et al. ¹²	2011	Single-center, open-label, split-face RCT	United States	20	95	N/A	N/A	LHA (5% or 10%) versus SA (20% or 30%)	<ul style="list-style-type: none"> ✧ Reduction of noninflammatory lesions ✧ Inflammatory lesion counts ✧ Global acne assessment ✧ Adverse events 	14
-------------------------------	------	---	---------------	----	----	-----	-----	---	--	----

AFA: amino fruit acid; AZA: azelaic acid; GA: glycolic acid; JS: Jessner’s solution; LHA: lipohydroxy acid; MA: mandelic acid; N/A: not available; PA: pyruvic acid; PDL: pulsed dye laser; RCT: randomized controlled trial; SA: salicylic acid; TCA: trichloroacetic acid.

Peer review only

Risk of bias in included studies

The methodological quality of included RCTs was generally low to moderate; however, in some cases, it was very low. The risk of bias in each included study is shown in Figure 2, with the percentage of each risk of bias item across studies summarized in Figure 3.

Effects of interventions

Due to significant differences across studies with regard to interventions (different chemical peels and regimens), outcomes, and follow-up durations, data from the different studies could not be combined to perform a meta-analysis. We identified a total of eight different chemical peels and grouped the data into 11 comparisons.

Comparison 1: Trichloroacetic acid peel versus salicylic acid peel

One RCT (20 participants, split-face comparison) compared 25% trichloroacetic acid (TCA; every 2 weeks, 4 sessions) to 30% salicylic acid (SA; every 2 weeks, 4 sessions) for the treatment of mild-to-moderate acne vulgaris. Skin lesions significantly improved, from baseline, in both treatment groups, with no significant difference between TCA and SA in terms of the percentage of total improvement for all lesions (85% vs. 95%; RR 0.89; 95% CI, 0.73-1.10), for noninflammatory lesions (80% vs. 70%; RR 1.14; 95% CI, 0.80-1.64), and for inflammatory lesions (80% vs. 85%; RR 0.94; 95% CI, 0.71-1.25).¹³

Adverse events

No adverse event was identified for the SA peel. For the TCA peel, four patients (20%) reported hyperpigmentation that lasted for 3 to 4 weeks.¹³

Comparison 2: SA peel versus phototherapy

One RCT (22 participants) compared 10% SA (once every week, 10 sessions) to phototherapy (once every week, 10 sessions). Both interventions significantly improved acne lesions, with no significant difference between the two interventions in terms of the reduction in the number of comedones (MD, 2.00; 95% CI, -3.67 to 7.67) and papules (MD, -1.00; 95% CI, -4.40 to 2.40). However, the SA peel did not reduce the number of pustules to the same extent as phototherapy (MD, -7.00; 95% CI, -10.84 to -3.16).¹⁴

Adverse events

No information regarding adverse effects was reported.¹⁴

Comparison 3: SA peel versus Jessner's solution peel

Two RCTs compared SA to Jessner's solution (JS) peels.^{15 16} Because of significant differences in the treatment regimen, measured outcomes, and follow-up duration, data from these two studies could not be combined for analysis.

One RCT (13 patients, split-face comparison) compared 30% SA (every 2 weeks, 3 sessions) to JS (every 2 weeks, 3 sessions).¹⁵ The authors stated that SA "seemed to be more effective than" JS for the treatment of noninflammatory lesions. However, relevant data supporting this conclusion were not clearly described. Furthermore, the authors reported that both SA and JS were effective in reducing inflammatory lesions;

1
2
3
4 however, they did not compare the effects of SA and JS on this outcome.

5
6 Another RCT (40 patients) also compared 30% SA (every 2 weeks, 6 sessions) to JS
7
8 (every 2 weeks, 6 sessions).¹⁶ SA was superior to JS in terms of overall percentage
9
10 decrease in the mean number of comedones (53.4% and 26.3%, respectively, $p=0.001$),
11
12 with equivalent outcomes for papules (71.0% and 61.5%, respectively, $p=0.870$) and
13
14 pustules (70.3% and 76.7%, respectively, $p=0.570$). The proportional decreases in the
15
16 mean Michaelson acne score (MAS), before and after treatment, were greater for SA
17
18 than for JS (60.4% and 34.1%, respectively, $p=0.002$).
19
20
21

22 23 Adverse events

24
25 Initial burning sensations, post-peeling erythema and mild scaling were common
26
27 symptoms that were comparable for the SA and JS groups.¹⁶ One patient reported
28
29 intense scaling on the side that was treated with SA.¹⁵ There was no report of
30
31 hyperpigmentation.
32
33

34
35 Dayal et al. reported that SA and JS were both well-tolerated, although SA induced
36
37 more burning and stinging sensation (65% and 45%, respectively; RR 2.27; 95% CI,
38
39 0.64-8.11; nonsignificant between-group difference).¹⁶ However, post-peeling
40
41 erythema was less common in the SA group than in the JS group (20% and 30%,
42
43 respectively; RR 0.58; 95% CI 0.14-2.50; nonsignificant between-group difference).
44
45 Hyperpigmentation was rare in both groups (5% and 15%, respectively; RR 0.30; 95%
46
47 CI, 0.30-3.15).
48
49
50

51 52 53 *Comparison 4: SA plus mandelic acid peel versus glycolic acid peel*

54
55 One RCT (40 patients) compared 20% SA plus 10% mandelic acid (MA; every 2
56
57

1
2
3
4 weeks, 6 sessions) to 35% glycolic acid (GA; every 2 weeks, 6 sessions).¹⁷ The
5
6 combination of SA and MA was superior to GA in terms of the percentage of
7
8 improvement, from baseline, in comedones (90.2% and 35.9%, respectively, $p<0.05$),
9
10 papules (81.7% and 77.8%, respectively, $p=0.006$), and pustules (85.4% and 75.7%,
11
12 respectively, $p<0.001$), as well as in the total acne score (85.3% and 68.5%,
13
14 respectively, $p<0.001$).

15 16 17 18 Adverse events

19
20 There was no significant difference between these two intervention groups in terms of
21
22 burning or stinging sensations (20% and 10%, respectively; RR, 2.00; 95% CI,
23
24 0.41-9.71), skin dryness (15% and 10%, respectively; RR, 1.50; 95% CI, 0.28-8.04),
25
26 and acne flare-up (10% each; RR, 1.00; 95% CI, 0.16-6.42). However, the
27
28 combination of SA and MA induced more visible desquamation than GA (80% and
29
30 40%, respectively; RR, 2.00; 95% CI, 1.12-3.57).

31 32 33 34 35 36 37 *Comparison 5: GA peel versus amino fruit acid peel*

38
39 One RCT (30 patients, split-face comparison) compared GA (at concentrations of
40
41 20%, 35%, 50%, and 70%; every 2 weeks, 12 sessions) to amino fruit acid (AFA) (at
42
43 similar concentrations of 20%, 30%, 40%, 50%, and 60%; every 2 weeks, 12
44
45 sessions).¹¹ Both peeling agents significantly improved acne lesions and had
46
47 comparable effectiveness in reducing the number of noninflammatory lesion counts
48
49 (MD, 2.35; 95% CI, -18.66 to 23.36), the reduction of inflammatory lesions (MD,
50
51 0.20; 95% CI, -3.03 to 3.43), and patient's choice of future treatment (GA, 45.8%;
52
53 AFA, 54.2%; RR, 0.85; 95% CI, 0.48-1.50).

Adverse events

All patients reported erythema at least once for both peels during the follow-up period. Edema was more common for GA than for AFA (91.7% and 50%, respectively; RR, 1.83; 95% CI, 1.21-2.78).¹¹ The incidence of frosting was comparable for both GA and AFA peels (29.2% vs. 16.7%, respectively; RR, 1.75; 95% CI, 0.59-5.21). Of note, all patients reported discomfort that negatively affected daily life with the GA peel.

Comparison 6: SA peel versus pyruvic acid peel

One RCT (86 patients) compared 30% SA (every 2 weeks, five sessions) to 50% pyruvic acid (PA; every 2 weeks, 5 sessions).¹⁸ The two peels had similar effects for reducing comedones (MD, 7.45; 95% CI, -18.46 to 33.36), papules (MD, -0.20; 95% CI, -5.36 to 4.96) and pustules (MD, -1.03; 95% CI, -2.01 to 0.05). The achievement of an excellent or good improvement in all lesions was comparable for both SA and PA peels (66.7% and 60%, respectively; RR, 1.11; 95% CI, 0.73-1.69).¹⁸

Adverse events

Burning sensations were very common (>85%) for both peels. The incidences of scaling, erythema and itching were also reported to be comparable (with no data presented). Hyperpigmentation was rare and comparable for the SA and PA peels (11.1% and 8%, respectively; RR, 1.39; 95% CI, 0.25-7.64).

Comparison 7: GA peel versus placebo

One RCT (25 patients, split-face comparison) compared 40% GA (every 2 weeks, 5 sessions) to a placebo (every 2 weeks, 5 sessions).¹⁹ GA was significantly superior to

1
2
3
4 the placebo for reducing the number of noninflammatory lesions (no data available,
5
6 $p < 0.01$), inflammatory lesions (no data available, $p < 0.01$) and total lesions (no data
7
8 available, $p < 0.01$).¹⁹ The achievement of excellent or good improvement in all lesions
9
10 was also superior for GA than for the placebo (92% vs. 40%, respectively; RR, 2.30;
11
12 95% CI, 1.40-3.77).

13 14 15 Adverse events

16
17 The authors reported that most patients experienced “transient post-treatment mild
18
19 erythema that lasted a few minutes at most”, but no supporting data were presented.¹⁹
20
21 Mild dryness was less common in the GA group than in the placebo group (28% and
22
23 100%, respectively; RR, 0.29; 95% CI, 0.16-0.54); however, the incidence of scaling
24
25 was comparable between the groups (16% and 12%, respectively; RR, 1.33; 95% CI,
26
27 0.33-5.38). A flare-up rate of 12% was reported for GA, whereas no flare-up was
28
29 reported for the placebo, although this difference was not significant (RR, 7.00; 95%
30
31 CI, 0.38-128.87).

32 33 34 35 36 37 38 *Comparison 8: GA peel versus SA peel*

39
40 One RCT (20 patients, split-face comparison) compared 30% GA (every 2 weeks, 6
41
42 sessions) to 30% SA (every 2 weeks, 6 sessions).²² Good or fair improvement in the
43
44 total number of lesions at 1 month post-treatment was achieved with both GA and SA
45
46 (94.1% each; RR, 1.00; 95% CI, 0.85-1.18). However, the mean number of all lesions
47
48 was significantly higher on the GA-treated side than on the SA-treated side after a
49
50 2-month follow-up with no treatment (no data available, $p < 0.01$). In terms of the
51
52 patients’ self-assessments, 41% of patients preferred GA, whereas 35% preferred SA
53
54
55
56

(RR, 1.17; 95% CI, 0.49-2.75).

Adverse events

The authors reported that both GA and SA were safe and well tolerated, with no difference in adverse events rates between the two peels. The most common adverse events were scaling, peeling, and erythema (no data available).

Comparison 9: GA peel versus JS peel

One RCT (26 patients, split-face comparison) compared 70% GA (every 2 weeks, 3 sessions) to JS (every 2 weeks, 3 sessions).²³ Both GA and JS had similar effects and improved acne scores by ≥ 0.5 (50% each; RR, 1.00; 95% CI, 0.58-1.72). Self-reported improvements were equivalent for GA and JS (30.7% and 30.7%, respectively; RR, 1.00; 95% CI, 0.44-2.26), as were the choices for future treatment (50% and 30.7%, respectively; RR, 1.63; 95% CI, 0.81-3.65).

Adverse events

Erythema was common for both peels (no data available). However, JS induced scaling that negatively influenced patients' daily life (GA, 0%; JS, 36%; RR, 0.05; 95% CI, 0-0.86). Two patients could not tolerate the 70% GA treatment due to the development of acute eczema, crusting, and oozing.

Comparison 10: TCA peel versus non-purpuric pulsed dye laser

One RCT (45 patients) compared 25% TCA peel (every 2 weeks, 6 sessions) to non-purpuric pulsed dye laser (every 2 weeks, 6 sessions).²⁴ The mean acne severity score was significantly improved, from baseline, for both TCA and laser therapy (MD

0.28; 95% CI, -0.33 to 0.89); the clinical response was equivalent for both agents (40% and 46.2%, respectively; RR, 0.87; 95% CI, 0.37-2.04). However, the mean remission period after treatment was significantly shorter for TCA than for laser therapy (MD -1.60 months; 95% CI, -1.85 to -1.35).

Adverse events

The authors classified adverse events as follows: none, trace, mild, moderate, and severe. No severe adverse events were reported. Two patients (13%) in the TCA peel group and three (23.1%) in the laser therapy group reported moderate adverse events (RR, 0.58; 95% CI, 0.11-2.94). Mild adverse events were reported for six patients (40%) in the TCA peel group and five (38.5%) in the laser therapy group (RR, 1.04; 95% CI, 0.41-2.62). Both treatments were considered to be well tolerated.

Comparison 11: Lipohydroxy acid peel versus SA peel

One RCT (20 patients) compared lipohydroxy acid (LHA; 5% or 10%, every 2 weeks, 6 sessions) to SA (20% or 30%, every 2 weeks, 6 sessions).¹² Both LHA and SA reduced the number of noninflammatory lesions (55.6% and 48.5%, respectively, $p=0.878$) and inflammatory lesions (no data available, $p=0.111$).

Adverse events

Both LHA and SA peels were well-tolerated. The global tolerance for the SA peel was better than that for the LHA peel upon patient assessment (no data available, $p=0.028$), but there was no difference investigator assessment (no data available, $p=0.546$).

DISCUSSION

To the best of our knowledge, this is the first systematic review addressing chemical peels for treating acne vulgaris. Based on our analysis of the data presented in the 12 included RCTs, chemical peeling is an overall positive method of treating acne vulgaris. The following comparisons demonstrated the equivalence of peels for the treatment of acne vulgaris: TCA vs. SA, GA vs. AFA, SA vs. PA, GA vs. SA, GA vs. JS, and LHA vs. SA. Moreover, the combination of SA and MA results in a more effective peeling than GA. Furthermore, SA was found to be more effective than JS for the treatment of comedones, but less effective than phototherapy in treating pustules. The effectiveness of TCA is comparable to that of pulsed dye laser therapy, but the laser provided a longer period of remission.

All chemical peels evaluated were well-tolerated. The most common adverse events were as follows: transient burning or stinging sensations, post-peeling erythema or scaling, and topical edema or dryness. A few patients reported acne flare-ups with the combination of SA and MA peel and with GA alone. Hyperpigmentation was a rare adverse event reported by patients treated with TCA, SA, and JS peels. Of note, this RCT did not have sufficient power to identify all adverse events, especially rare adverse events, due to the limited sample size.²⁵

The information provided in our review may assist dermatologists with selecting the most appropriate chemical peels to treat acne vulgaris. However, our findings should be considered with caution because the included RCTs were performed in different countries and recruited individuals of different ethnicities. The choice of chemical

1
2
3
4 peels should be individualized, based on the patient's skin type, history of acne or
5
6 other skin diseases and relevant treatments, and expectations. For example, chemical
7
8 peels, especially medium or deep peels, are unsuitable for those with a Fitzpatrick
9
10 skin type V or VI, because these peels may cause dyspigmentation and scarring in
11
12 these patients.^{26 27} In fact, most included studies recruited patients with a Fitzpatrick
13
14 skin type I through IV, although some studies did not report the skin type. In addition,
15
16 most included studies focused on mild-to-moderate acne.
17
18

19
20 There is currently no consensus regarding the standardized regimen for chemical
21
22 peeling, because the optimal concentration, treatment interval, and duration for
23
24 different chemical peels remain unclear. In our review, the regimen of chemical peels
25
26 varied significantly across studies. For example, the concentration of GA used in
27
28 different RCTs varied from 10% to 70%, and the treatment durations varied from 6 to
29
30 24 weeks. Studies are warranted to compare different regimens of the same chemical
31
32 peel in order to determine the optimal regimen for each peeling agent.
33
34

35
36 There is an emerging trend of using a combination of peeling agents because of the
37
38 belief that better clinical results can be achieved while reducing the risk of adverse
39
40 events.³ For instance, Vitalize Peel[®] contains both SA and lactic acid, while
41
42 Micropeel Plus[®] contains SA and GA for treating acne vulgaris.⁵ However, we could
43
44 not find any RCT to confirm the efficacy of the premixed chemical peeling agents for
45
46 acne. In the future, more attention should be focused on these premixed formulations
47
48 of chemical peels.
49
50

51
52 In this review, we surprisingly found that only one RCT¹⁹ compared a chemical
53
54

1
2
3 peeling agent (GA) to placebo for acne vulgaris. However, more than 10 chemical
4
5 peeling agents have actually been applied. Further well-designed RCTs are needed to
6
7 compare other chemical peels to placebo. A network meta-analysis based on these
8
9 RCTs should provide more valuable and robust evidence for clinical practice.
10
11 Additionally, the outcome measurements were significantly different across the
12
13 included RCTs, which made it difficult to compare or merge the results of different
14
15 studies. Therefore, we suggest that the future version of the guideline of care for the
16
17 management of acne vulgaris should make recommendations regarding the standard
18
19 of outcome measurements. Our review has some limitations. First, all included studies
20
21 were of very low-to-moderate methodological quality with small sample sizes, which
22
23 might have introduced bias. However, we evaluated for bias in each study. For
24
25 example, most of the included RCTs did not describe the method of randomization. It
26
27 is important to adhere to the recommendations of the Consolidated Standards of
28
29 Reporting Trials (CONSORT) statement to avoid incomplete and inadequate reporting
30
31 and to improve the quality of the evidence.²⁸ Second, this review did not investigate
32
33 the effects of chemical peeling for acne scarring, although chemical peels are used
34
35 clinically for this indication.⁶ Finally, as previously discussed, the absence of a
36
37 standardized peeling regimen limits the translation of our findings to clinical practice.
38
39
40
41
42
43
44
45
46
47

48 **CONCLUSIONS**

49 **Implication for practice**

50
51
52
53
54
55 Commonly used chemical peels appear to be similarly effective for mild-to-moderate
56
57

1
2
3 acne vulgaris and well-tolerated. However, based on current limited evidence, we
4
5
6 could not draw a robust conclusion regarding any definitive superiority or equality
7
8
9 among the currently used agents for chemical peeling.

10 11 **Implications for research**

12
13
14
15 Well-designed and well-reported RCTs are needed to provide high quality evidence to
16
17 inform practice, particularly regarding the optimal formulation and regimen for
18
19 chemical peeling agents. Comparisons with placebo or each other should be
20
21 performed for various ethnic populations and skin types. In addition, standard
22
23 outcome measurements for the management of acne vulgaris are needed.
24
25
26
27

28 **ACKNOWLEDGEMENT**

29
30
31 None.

32 33 **COMPETING INTERESTS**

34
35
36 All authors have not conflict of interest to declare.
37
38
39
40

41 **CONTRIBUTORS**

42
43
44 XC and LL designed the protocol. XC and MY searched the literature, extracted the
45
46 data, and analysed the data. XC, SW, MY and LL interpreted the data and revised the
47
48 manuscript.
49
50
51
52
53
54
55
56
57
58
59
60

FUNDING

This review was supported by a grant from the Sichuan Provincial Science and Technology Department (Grant number: 2017JY0277).

DISCLAIMER

The funder had no role in study design, data collection, data analysis, data interpretation or writing of the report.

DATA SHARING STATEMENT

No additional data are available.

REFERENCES

1. Sathish D, Shayeda, Rao YM. Acne and its treatment options: a review. *Curr Drug Deliv* 2011;8(6):634-9.
2. Bhate K, Williams HC. Epidemiology of acne vulgaris. *Br J Dermatol* 2013;168(3):474-85. doi: 10.1111/bjd.12149
3. Kontochristopoulos G, Platsidaki E. Chemical peels in active acne and acne scars. *Clinics in Dermatology* 2017;35(2):179-82.
4. Salam A, Dadzie OE, Galadari H. Chemical peeling in ethnic skin: an update. *British Journal of Dermatology* 2013;169 Suppl 3:82-90.
5. Jackson A. Chemical peels. *Facial Plast Surg* 2014;30(1):26-34. doi: 10.1055/s-0033-1364220

- 1
2
3
4 6. Abdel Hay R, Shalaby K, Zaher H, et al. Interventions for acne scars.
5
6 *Cochrane Database of Systematic Reviews* 2016;4:CD011946.
7
- 8
9 7. Arif T. Salicylic acid as a peeling agent: a comprehensive review. *Clinical,*
10
11 *Cosmetic and Investigational Dermatology CCID* 2015;8:455-61.
12
- 13
14 8. Dreno B, Fischer TC, Perosino E, et al. Expert opinion: efficacy of superficial
15
16 chemical peels in active acne management--what can we learn from the
17
18 literature today? Evidence-based recommendations. *Journal of the*
19
20 *European Academy of Dermatology & Venereology*
21
22 2011;25(6):695-704.
23
- 24
25 9. Sharad J. Glycolic acid peel therapy - a current review. *Clinical, Cosmetic*
26
27 *and Investigational Dermatology CCID* 2013;6:281-8.
28
- 29
30 10. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the
31
32 management of acne vulgaris. *J Am Acad Dermatol* 2016;74(5):945-73
33
34 e33. doi: 10.1016/j.jaad.2015.12.037
35
- 36
37 11. Ilknur T, Demirtasoglu M, Bicak MU, et al. Glycolic acid peels versus amino
38
39 fruit acid peels for acne. *Journal of Cosmetic & Laser Therapy*
40
41 2010;12(5):242-5.
42
- 43
44 12. Levesque A, Hamzavi I, Seite S, et al. Randomized trial comparing a
45
46 chemical peel containing a lipophilic hydroxy acid derivative of salicylic
47
48 acid with a salicylic acid peel in subjects with comedonal acne. *Journal*
49
50 *of Cosmetic Dermatology* 2011;10(3):174-8.
51
52
- 53
54 13. Abdel Meguid AM, Elaziz Ahmed Attallah DA, Omar H. Trichloroacetic Acid
55
56

- 1
2
3 Vs. Salicylic Acid in the Treatment of Acne Vulgaris in Dark-Skinned
4
5
6 Patients. *Dermatologic Surgery* 2015;41(12):1398-404.
7
8
9 14. Alba MN, Gerenutti M, Yoshida VM, et al. Clinical comparison of salicylic
10
11 acid peel and LED-Laser phototherapy for the treatment of Acne
12
13 vulgaris in teenagers. *Journal of Cosmetic & Laser Therapy*
14
15 2017;19(1):49-53.
16
17
18 15. Bae BG, Park CO, Shin H, et al. Salicylic acid peels versus Jessner's
19
20 solution for acne vulgaris: a comparative study. *Dermatologic Surgery*
21
22 2013;39(2):248-53.
23
24
25 16. Dayal S, Amrani A, Sahu P, et al. Jessner's solution vs. 30% salicylic acid
26
27 peels: a comparative study of the efficacy and safety in
28
29 mild-to-moderate acne vulgaris. *J Cosmet Dermatol* 2017;16(1):43-51.
30
31
32 doi: 10.1111/jocd.12266
33
34
35 17. ElRefaei AM, Abdel Salam HA, Sorour NE. Salicylic-mandelic acid versus
36
37 glycolic acid peels in Egyptian patients with acne vulgaris. *Journal of the*
38
39 *Egyptian Women's Dermatologic Society* 2015;12(3):196-202.
40
41
42 18. Jaffary F FGSSHSM. Comparison the effectiveness of pyruvic acid 50%
43
44 and salicylic acid 30% in the treatment of acne. *Journal of research in*
45
46 *medical sciences* 2016;21(2)
47
48
49 19. Kaminaka C, Uede M, Matsunaka H, et al. Clinical evaluation of glycolic
50
51 acid chemical peeling in patients with acne vulgaris: a randomized,
52
53 double-blind, placebo-controlled, split-face comparative study.
54
55
56

- 1
2
3
4 *Dermatologic Surgery* 2014;40(3):314-22.
- 5
6 20. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for
7
8 systematic reviews and meta-analyses: the PRISMA statement. *BMJ*
9
10 2009;339:b2535. doi: 10.1136/bmj.b2535
- 11
12
13 21. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of
14
15 Interventions Version 5.1.0 [updated March 2011]: The Cochrane
16
17 Collaboration; 2011 [Available from: www.handbook.cochrane.org].
- 18
19
20 22. Kessler E, Flanagan K, Chia C, et al. Comparison of alpha- and
21
22 beta-hydroxy acid chemical peels in the treatment of mild to moderately
23
24 severe facial acne vulgaris. *Dermatologic Surgery* 2008;34(1):45-50;
25
26 discussion 51.
- 27
28
29 23. Kim SW, Moon SE, Kim JA, et al. Glycolic acid versus Jessner's solution:
30
31 which is better for facial acne patients? A randomized prospective
32
33 clinical trial of split-face model therapy. *Dermatologic Surgery*
34
35 1999;25(4):270-3.
- 36
37
38 24. Leheta TM. Role of the 585-nm pulsed dye laser in the treatment of acne in
39
40 comparison with other topical therapeutic modalities. *Journal of*
41
42 *Cosmetic & Laser Therapy* 2009;11(2):118-24.
- 43
44
45 25. Wahab IA, Pratt NL, Kalisch LM, et al. The detection of adverse events in
46
47 randomized clinical trials: can we really say new medicines are safe?
48
49
50 *Current drug safety* 2013;8(2):104-13. [published Online First:
51
52 2013/05/30]
- 53
54
55
56
57
58
59
60

- 1
2
3
4 26. Been MJ, Mangat DS. Laser and face peel procedures in non-Caucasians.
5
6 *Facial Plastic Surgery Clinics of North America* 2014;22(3):447-52.
7
8
9 27. Handog EB, Datuin MS, Singzon IA. Chemical peels for acne and acne
10
11 scars in asians: evidence based review. *Journal of Cutaneous &*
12
13 *Aesthetic Surgery* 2012;5(4):239-46.
14
15
16 28. Boutron I, Altman DG, Moher D, et al. CONSORT Statement for
17
18 Randomized Trials of Nonpharmacologic Treatments: A 2017 Update
19
20 and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Ann*
21
22 *Intern Med* 2017;167(1):40-47. doi: 10.7326/M17-0046
23
24
25

26 **FIGURE LEGEND**

27
28
29 Figure 1. Preferred Reporting Items for the Systematic Reviews (PRISMA) diagram
30
31 of the study flow.
32

33
34 Figure 2. Risk of bias summary for each study.
35

36
37 Figure 3. Risk of bias summary graph for all included studies.
38
39
40
41
42

43 **SUPPLEMENTARY FILES**

44
45
46 Supplementary Table 1. The search strategies for MEDLINE, EMBASE and
47
48 CENTRAL via OvidSP.
49

50
51 Supplementary Table 2. Reasons for study exclusion
52
53
54
55
56
57
58
59
60




Figure 1. Preferred Reporting Items for Systematic Reviews (PRISMA) diagram of the study flow.

213x260mm (300 x 300 DPI)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Abdel 2015	●	●	●	+	+	+	?
Alba 2017	?	?	●	+	+	+	?
Bae 2013	?	?	●	+	+	+	?
Dayal 2017	+	?	?	+	?	+	?
EIRefaei 2015	?	+	●	●	+	+	?
Ilknur 2010	?	?	?	+	●	+	?
Jaffary 2016	?	?	?	?	●	+	?
Kaminaka 2014	?	?	+	+	+	+	?
Kessler 2008	?	?	?	+	●	+	?
Kim 1999	+	?	●	?	?	+	?
Leheta 2009	?	?	●	?	+	+	?
Levesque 2011	+	+	?	+	●	+	+
Majid 2013	+	?	?	+	+	+	?

Figure 2. Risk of bias summary for each study.

138x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Risk of bias summary graph of all included studies.

209x87mm (300 x 300 DPI)

Peer review only

Supplementary Table 1. Search strategies for searching MEDLINE, EMBASE, and CENTRAL via OvidSP

No.	Searches
1	(chemical adj (peel* or resurface*).ab,kw,ti. ((hydroxy or glycolic or lactic or malic or citric or tartaric or salicylic or trichloroacetic or pyruvic or lipohydroxy or salicylic-mandelic or "amino fruit") adj acid*).ab,kw,ti.
2	adj acid*).ab,kw,ti.
3	("Jessner's solution" or "Jessner's solutions").ab,kw,ti.
4	(resorcinol* or phenol*).ab,kw,ti.
5	acne.ab,kw,ti.
6	exp *Acne Vulgaris/
7	1 or 2 or 3 or 4
8	5 or 6
9	7 and 8
10	remove duplicates from 9

Supplementary Table 2. Reasons for study exclusion

Studies	Reason for exclusion
Garg 2009 ¹	This study is not an RCT.
Kim 2015 ²	This RCT compared alpha hydroxy acids plus an additional physical treatment with alpha hydroxy acids alone.
Lee 2006 ³	This study is not an RCT.
Lekakh 2015 ⁴	This study compared chemical peel and the combination of laser and chemical peel.
Nofal 2014 ⁵	This study appears to be not an RCT because of the significant difference between the method section and the abstract about the randomization. And there is no reply from the authors to clarify this inconsistency.
Sharad 2011 ⁶	This study is not an RCT
Wang 1997 ⁷	This study is not an RCT

RCT: randomized controlled trial.

References of the excluded studies:

1. Garg VK, Sinha S , Sarkar R. Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. *Dermatologic Surgery* 2009;35:59-65.
2. Kim SJ, Baek JH, Koh JS, Bae MI, Lee SJ , Shin MK. The effect of physically applied

1
2
3
4 alpha hydroxyl acids on the skin pore and comedone. International Journal of
5
6 Cosmetic Science 2015;37:519-25.

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3. Lee SH, Huh CH, Park KC , Youn SW. Effects of repetitive superficial chemical peels on facial sebum secretion in acne patients. Journal of the European Academy of Dermatology & Venereology 2006;20:964-8.

4. Lekakh O, Mahoney AM, Novice K, Kamalpour J, Sadeghian A, Mondo D et al. Treatment of Acne Vulgaris With Salicylic Acid Chemical Peel and Pulsed Dye Laser: A Split Face, Rater-Blinded, Randomized Controlled Trial. Journal of Lasers in Medical Sciences 2015;6:167-70.

5. Nofal E, Helmy A, Nofal A, Alakad R , Nasr M. Platelet-rich plasma versus CROSS technique with 100% trichloroacetic acid versus combined skin needling and platelet rich plasma in the treatment of atrophic acne scars: a comparative study. Dermatologic Surgery 2014;40:864-73.

6. Sharad J. Combination of microneedling and glycolic acid peels for the treatment of acne scars in dark skin. Journal of Cosmetic Dermatology 2011;10:317-23.

7. Wang CM, Huang CL, Hu CT , Chan HL. The effect of glycolic acid on the treatment of acne in Asian skin. Dermatologic Surgery 1997;23:23-9.



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5-6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supplementary table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	-
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Not necessary

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	-
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Not necessary
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Fig 2 and 3
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	12-19
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Meta-analysis is not possible to be performed.
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	-
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Not necessary
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	20-21
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	22

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only